Vorinostat | SAHA;Suberoylanilide hydroxamic acid;MK-0683, MK 0683, MK0683, SAHA, M344, CCRIS 8456, HSDB 7930, Vorinostat, suberoylanilide hydroxamic acid, Zolinza;MK0683 | N-羟基-N'-苯基辛二酰胺 | HDAC | Autophagy

首页 / / / / Vorinostat/伏立诺他

Vorinostat/伏立诺他 {[allProObj[0].p_purity_real_show]}

货号：A234507 同义名： N-羟基-N'-苯基辛二酰胺 / SAHA; Suberoylanilide hydroxamic acid

Vorinostat (SAHA) 是一种高效、口服活性的 HDAC1、HDAC2、HDAC3 (I 类)、HDAC6、HDAC7 (II 类) 和 HDAC11 (IV 类) 的泛抑制剂，对 HDAC1 和 HDAC3 的 ID50 分别为 10 nM 和 20 nM。伏立诺他诱导细胞凋亡并抑制 HPV-18 DNA 扩增。

Vorinostat/伏立诺他化学结构
CAS号：149647-78-9

Vorinostat/伏立诺他 3D分子结构
CAS号：149647-78-9

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]}	现货	1周咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Vorinostat/伏立诺他纯度/质量文件产品仅供科研

货号：A234507 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Nature, 2025, 645, 793-800. Ambeed. [ A201204 , A444152 , A344107 , A952055 ]; • Cell, 2025. Ambeed. [ A122167 ]; • Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]; • Sig. Transduct. Target. Ther., 2025, 10, 257. Ambeed. [ A104916 ]; • Nat. Nanotechnol., 2025. Ambeed. [ A243018 , A1216705 , A522597 , A125401 , A1355641 ]; 更多 >

组蛋白去乙酰化酶亚型比较
自噬亚型比较

产品名称	HD1 ↓ ↑	HD2 ↓ ↑	HDAC ↓ ↑	HDAC1 ↓ ↑	HDAC10 ↓ ↑	HDAC11 ↓ ↑	HDAC2 ↓ ↑	HDAC3 ↓ ↑	HDAC4 ↓ ↑	HDAC5 ↓ ↑	HDAC6 ↓ ↑	HDAC7 ↓ ↑	HDAC8 ↓ ↑	HDAC9 ↓ ↑	其他靶点	纯度
Givinostat HCl monohydrate	++++ HD1-A, IC50: 16 nM HD1-B, IC50: 7.5 nM	+++ HD2, IC50: 10 nM														99%+
MC1568	++ HD1-B (Maize), IC50: 3.4 μM HD1-A (Maize), IC50: 100 nM															96%
Trichostatin A			++++ HDAC, IC50: ~1.8 nM													99%+
Scriptaid			✔													99%+
Valproic acid sodium			✔												Autophagy	97%
AR-42			+++ HDAC, IC50: 30 nM													99%+
Dacinostat			+++ HDAC, IC50: 32 nM													98+%
CUDC-101			++++ HDAC, IC50: 4.4 nM	++++ HDAC1, IC50: 4.5 nM	+++ HDAC10, IC50: 26.1 nM		+++ HDAC2, IC50: 12.6 nM	++++ HDAC3, IC50: 9.1 nM	+++ HDAC4, IC50: 13.2 nM	+++ HDAC5, IC50: 11.4 nM	++++ HDAC6, IC50: 5.1 nM	+ HDAC7, IC50: 373 nM	++ HDAC8, IC50: 79.8 nM	++ HDAC9, IC50: 67.2 nM	EGFR,HER2	99%+
M344			++ HDAC, IC50: 100 nM													99%+
Splitomicin			+ Sir2p, IC50: 60 μM													99%
Panobinostat			++++ HDAC (Reh cells), IC50: 20 nM HDAC (MOLT-4 cells), IC50: 5 nM													98%
Sodium 4-Phenylbutyrate			✔													98%
Vorinostat			+++ HDAC, IC50: ~10 nM													98%
Curcumin			✔												NF-κB,Nrf2	98%
Belinostat			+++ HDAC, IC50: 27 nM													98%
RG-2833				++ HDAC1, Ki: 32 nM				++ HDAC3, Ki: 5 nM								98%
Valproic acid				+ HDAC1, IC50: 0.4 mM												98%
BG45				+ HDAC1, IC50: 2 μM			+ HDAC2, IC50: 2.2 μM	+ HDAC3, IC50: 289 nM								99%+
Entinostat				+ HDAC1, IC50: 0.51 μM				+ HDAC3, IC50: 1.7 μM								98%
Resminostat				+++ HDAC1, IC50: 42.5 nM				++ HDAC3, IC50: 50.1 nM			++ HDAC6, IC50: 71.8 nM					98+%
Romidepsin				+++ HDAC1, IC50: 36 nM			+++ HDAC2, IC50: 47 nM									99%+
Parthenolide				✔											NF-κB,p53	97% HPLC
Tacedinaline				+ HDAC1, IC50: 0.9 μM			+ HDAC2, IC50: 0.9 μM	+ HDAC3, IC50: 1.2 μM								98%
Mocetinostat				++ HDAC1, IC50: 0.15 μM		+ HDAC11, IC50: 0.59 μM	+ HDAC2, IC50: 0.29 μM	+ HDAC3, IC50: 1.66 μM								98%
WT-161				++++ HDAC1, IC50: 8.35 nM			+++ HDAC2, IC50: 15.4 nM				++++ HDAC6, IC50: 0.4 nM					99%+
Fimepinostat				++++ HDAC1, IC50: 1.7 nM	++++ HDAC10, IC50: 2.8 nM	++++ HDAC11, IC50: 5.4 nM	++++ HDAC2, IC50: 5.0 nM	++++ HDAC3, IC50: 1.8 nM			+++ HDAC6, IC50: 27 nM					99%+
Tucidinostat				++ HDAC1, IC50: 95 nM	++ HDAC10, IC50: 78 nM		++ HDAC2, IC50: 160 nM	++ HDAC3, IC50: 67 nM								99%+
Santacruzamate A							++++ HDAC2, IC50: 119 pM									99%+
(E,E)-RGFP966								++ HDAC3, IC50: 80 nM								99%+
LMK-235									+++ HDAC4, IC50: 11.9 nM	++++ HDAC5, IC50: 4.2 nM						99%+
Tasquinimod									✔							99%+
CAY10603											++++ HDAC6, IC50: 2 pM					98%
Tubastatin A											+++ HDAC6, IC50: 15 nM					98%
Tubacin											++++ HDAC6, IC50: 4 nM					99%+
ACY-738											++++ HDAC6, IC50: 1.7 nM					99%+
Nexturastat A											++++ HDAC6, IC50: 5 nM					99%+
BRD73954											+++ HDAC6, IC50: 36 nM		++ HDAC8, IC50: 120 nM			99%
Tubastatin A HCl											+++ HDAC6, IC50: 15 nM		+ HDAC8, IC50: 854 nM			98%
PCI-34051													+++ HDAC8, IC50: 10 nM			99%+
Ricolinostat				++ HDAC1, IC50: 58 nM			++ HDAC2, IC50: 48 nM	++ HDAC3, IC50: 51 nM			++++ HDAC6, IC50: 4.7 nM		++ HDAC8, IC50: 100 nM			99%+
Droxinostat								+ HDAC3, IC50: 16.9 μM			+ HDAC6, IC50: 2.47 μM		+ HDAC8, IC50: 1.46 μM			99%+
Abexinostat				++++ HDAC1, Ki: 7 nM	+++ HDAC10, IC50: 24 nM		+++ HDAC2, Ki: 19 nM	++++ HDAC3/SMRT, Ki: 8.2 nM			+++ HDAC6, Ki: 17 nM		+ HDAC8, IC50: 280 nM			98%+
Citarinostat				+++ HDAC1, IC50: 35 nM			+++ HDAC2, IC50: 45 nM	+++ HDAC3, IC50: 46 nM			++++ HDAC6, IC50: 2.6 nM		++ HDAC8, IC50: 137 nM			99%+
HPOB				+ HDAC1, IC50: 2.9 μM	+ HDAC10, IC50: 3.0 μM		+ HDAC2, IC50: 4.4 μM	+ HDAC3, IC50: 1.7 μM			++ HDAC6, IC50: 56 nM		+ HDAC8, IC50: 2.8 μM			97%
Quisinostat 2HCl				++++ HDAC1, IC50: 0.11 nM	++++ HDAC10, IC50: 0.46 nM	++++ HDAC11, IC50: 0.37 nM	++++ HDAC2, IC50: 0.33 nM	++++ HDAC3, IC50: 4.86 nM	++++ HDAC4, IC50: 0.64 nM	++++ HDAC5, IC50: 3.69 nM			++++ HDAC8, IC50: 4.26 nM			97%
Domatinostat				+ HDAC1, IC50: 1.20 μM	+ HDAC10, IC50: 21 μM	+ HDAC11, IC50: 9.7 μM	+ HDAC2, IC50: 1.12 μM	+ HDAC3, IC50: 0.57 μM		+ HDAC5, IC50: 11.3 μM				+ HDAC9, IC50: 50 μM		99%+
TMP269									++ HDAC4, IC50: 157 nM	++ HDAC5, IC50: 97 nM		+++ HDAC7, IC50: 43 nM		+++ HDAC9, IC50: 23 nM		99%+
Pracinostat				++ HDAC1, IC50: 49 nM	+++ HDAC10, IC50: 40 nM	++ HDAC11, IC50: 93 nM	++ HDAC2, IC50: 96 nM	+++ HDAC3, IC50: 43 nM	++ HDAC4, IC50: 56 nM	+++ HDAC5, IC50: 47 nM	+ HDAC6, IC50: 1.008 μM	++ HDAC7, IC50: 137 nM	++ HDAC8, IC50: 140 nM	++ HDAC9, IC50: 70 nM		99%+
TMP195									++ HDAC4, Ki: 59 nM	++ HDAC5, Ki: 60 nM		+++ HDAC7, Ki: 26 nM		+++ HDAC9, Ki: 15 nM		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	Autophagy ↓ ↑	其他靶点	纯度
SBI-0206965	+++ ULK2, IC50: 711 nM ULK1, IC50: 108 nM		95%
Hydroxychloroquine sulfate	✔		99%
Valproic acid sodium	✔	HDAC	97%
PFK-015	++ PFKFB3, IC50: 207 nM		99%+
MRT68921 HCl	++++ ULK2, IC50: 1.1 nM ULK1, IC50: 2.9 nM		99%+
ROC-325	✔		99%+
Autophinib	+++ Autophagy, IC50: 40 nM		99%
Lys05	✔		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Vorinostat/伏立诺他生物活性

靶点	HDAC HDAC, IC50:~10 nM
描述	HDACs (Histone deacetylases) are a group of enzymes that remove acetyl groups and regulate the histone tail, protein-DNA interaction, chromatin conformation, and even transcription. There are 18 mammalian HDACs divided into four classes: class I (HDACs 1, 2, 3, 8), class II (HDACs 4, 5, 6, 7, 9, 10), class III (sirtuin family: sirt1-sirt7) and class IV (HDAC 11)^[1]. Vorinostat, also called as SAHA or MK0683, is a hydroxamic acid based class I and II HDACs pan inhibitor with IC50 value of 10nM on HDAC1 and 20 nM on HDAC3 (measured by immunoprecipitation–HDAC assays)^[2]. Treatement with 6 μM of vorinostat in SH-SY5Y cells for 1 - 12 hours can increase the acetylation signals of histone H3 and H4 in a time-dependent manner. Vorinostat can induce cell-growth inhibition in SH-SY5Y cell line with IC50 value of 2.5 μM and 10 μM at 72h and 48h, respectively. SILAC-based quantitative MS analysis show that SAHA has a dramatic impact on histone lysine acetylation and butyrylation with strong increase in H3K9ac, H3K27ac, H2BK5bu and H4K12bu of SHSY5Y cells. Vorinostat is clinically approved for cutaneous T-cell lymphoma^[3]. Both of gene expression and function of proteins regulating cell proliferation and cell death pathways are involved in the anticancer effects of SAHA, including TFIIB, Rb, Hsp90, Bcl-2 family, tubulin, HIF-1a, ROS, etc.^[4].
作用机制	Vorinostat, structurally similar to TSA, chelates the zinc ion of HDACs by its hydroxamic group^[5].

Vorinostat/伏立诺他细胞实验

Cell Line Breast cancer cells (MDA-MB-231) Prostate cancer cells (LNCaP) HCT-8 cells	Concentration	Treated Time	Description	References
Breast cancer cells (MDA-MB-231)	1 µM and 3 µM	5 h daily for 4 consecutive days	Vorinostat significantly decreased HDAC activity and inhibited cellular proliferation in a dose-dependent manner, with no significant effect on cell viability.	Oncotarget. 2016 Feb 16;7(7):7390-402.
Prostate cancer cells (LNCaP)	1 µM and 3 µM	5 h daily for 4 consecutive days	Vorinostat significantly decreased HDAC activity and inhibited cellular proliferation in a dose-dependent manner, with no significant effect on cell viability.	Oncotarget. 2016 Feb 16;7(7):7390-402.
HCT-8 cells	203 nM	44 h	To evaluate the inhibitory effect of Vorinostat on the growth of Cryptosporidium parvum, the results showed that Vorinostat significantly inhibited parasite growth in vitro.	J Infect Dis. 2018 Mar 13;217(7):1110-1117.

Vorinostat/伏立诺他动物实验

Species Nude mice Mice Nude mice	Animal Model DU145 xenograft model IL-12 knockout mouse model HuCC-T1 tumor model	Administration	Dosage	Frequency	Description	References
Nude mice	DU145 xenograft model	SAHA intraperitoneal injection, veliparib oral gavage	25 mg/kg/d	3 continuous weeks	To validate the antitumor effect of SAHA and veliparib co-treatment. Results showed that co-treatment significantly inhibited tumor growth.	J Exp Clin Cancer Res. 2018 Jul 16;37(1):153.
Mice	IL-12 knockout mouse model	Oral	7.5 mg/kg	Once daily for 6 days	To evaluate the inhibitory effect of Vorinostat on Cryptosporidium parvum infection in vivo, the results showed that Vorinostat significantly reduced the production of parasite oocysts.	J Infect Dis. 2018 Mar 13;217(7):1110-1117.
Nude mice	HuCC-T1 tumor model	Subcutaneous injection	10 mg/kg		Vorinostat nanofibers showed higher inhibition of tumor growth in HuCC-T1 tumor-bearing mice.	Int J Nanomedicine. 2017 Oct 17;12:7669-7680

Vorinostat/伏立诺他动物研究

Dose

Mice (i.p.): min = 50 mg/kg^[6], max = 200 mg/kg^[7]

Administration

i.p.

Pharmacokinetics

Animal	Mice^[8]
Dose	30 mg/kg
Administration	i.p.
C_max	26207 ng/ml
T_1/2	0.95 h
CL/F	98 ml/min/kg
AUC_0→t	5109 ng·h/ml
V_z/F	8 l/kg

Vorinostat/伏立诺他临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT00771472	Lymphoma	Phase 1	Completed	-	-
NCT00771472	-		Completed	-	-
NCT01064921	Stage III Squamous Cell Carcin... 展开 >>oma of the Oropharynx Stage IV Squamous Cell Carcinoma of the Oropharynx 收起 <<	Phase 1	Completed	-	United States, Ohio ... 展开 >> The Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43210 收起 <<

Vorinostat/伏立诺他参考文献

[1]Yoon S, Eom GH, et al. HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases. Chonnam Med J. 2016 Jan;52(1):1-11.

[2]Richon VM, Emiliani S, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3003-7.

[3]Xu G, Wang J, et al. SAHA regulates histone acetylation, Butyrylation, and protein expression in neuroblastoma. J Proteome Res. 2014 Oct 3;13(10):4211-9.

[4]Marks PA, et al. Discovery and development of SAHA as an anticancer agent. Oncogene. 2007 Feb 26;26(9):1351-6.

[5]Finnin MS, Donigian JR, et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature. 1999 Sep 9;401(6749):188-93.

[6]Hrzenjak A, Moinfar F, et al. Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo. Mol Cancer. 2010 Mar 4;9:49.

[7]Akada H, Akada S, et al. Efficacy of vorinostat in a murine model of polycythemia vera. Blood. 2012 Apr 19;119(16):3779-89.

[8]Nidhyanandan S, Thippeswamy BS, et al. Enhanced anticancer efficacy of histone deacetyl inhibitor, suberoylanilide hydroxamic acid, in combination with a phosphodiesterase inhibitor, pentoxifylline, in human cancer cell lines and in-vivo tumor xenografts. Anticancer Drugs. 2017 Oct;28(9):1002-1017.

Vorinostat/伏立诺他实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

3.78mL

0.76mL

0.38mL

18.92mL

3.78mL

1.89mL

37.83mL

7.57mL

3.78mL

Vorinostat/伏立诺他技术信息

CAS号	149647-78-9
分子式	C₁₄H₂₀N₂O₃
分子量	264.32
SMILES Code	O=C(NO)CCCCCCC(NC1=CC=CC=C1)=O
MDL No.	MFCD00945317

别名	N-羟基-N'-苯基辛二酰胺 ;SAHA; Suberoylanilide hydroxamic acid; MK-0683, MK 0683, MK0683, SAHA, M344, CCRIS 8456, HSDB 7930, Vorinostat, suberoylanilide hydroxamic acid, Zolinza; MK0683
运输	蓝冰
InChI Key	WAEXFXRVDQXREF-UHFFFAOYSA-N
Pubchem ID	5311

存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Keep in dark place, inert atmosphere, store in freezer, under -20°C

溶解方案

细胞实验：

DMSO: 105 mg/mL(397.25 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验：请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

方案二

方案三

方案四

方案五

配制的工作液建议现用现配，短期内尽快用完。以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

方案一

大规格询价

* 公司或机构名称：

* 姓名：

* 电话：

* 邮箱： * 国家/区域： * 需求量：

* 货号：

* CAS号：

* 产品名称：在线留言：

请填写此表格索取QC报告。我们很快就会发送到您的邮箱。您的信息在我们这里是安全的。*是必填项.

产品名称： * 货号：

* 姓名：

* 电话：

* 邮箱： * 公司或机构名称： * 部门：留言给我们：

摩尔计算器

计算溶液所需的质量，体积或浓度。 Ambeed 摩尔浓度计算器基于以下方程式：

浓度 (mol/L) × 体积 (L) × 分子量 (g/mol)=质量 (g)

浓度

体积

分子量

质量

*在制备母液时，请始终参考产品标签或 MSDS / COA（在产品页面可下载）上所显示的对应批次产品的分子量。

靶点

靶点	数值

HDAC	HDAC, IC50:~10 nM

总药量计算器

动物实验：给药剂量 mg/kg 动物体重 g 动物数量只每天给药次给药天

需要的总药量： mg

工作液计算器

动物实验：给药剂量 mg/kg 动物体重 g 给药体积 μL

您需要配制的工作液浓度为：mg/mL

细胞研究

细胞系	浓度	检测类型	检测时间	活性说明	数据源

22RV1		Growth Inhibition Assay		IC50=2.59274 μM	SANGER
5637		Growth Inhibition Assay		IC50=2.32129 μM	SANGER
639-V		Growth Inhibition Assay		IC50=3.46057 μM	SANGER
647-V		Growth Inhibition Assay		IC50=5.99148 μM	SANGER
697		Growth Inhibition Assay		IC50=473.41 nM	SANGER
769-P		Growth Inhibition Assay		IC50=5.86718 μM	SANGER
786-0	6.2 μM	Growth Inhibition Assay	72 h	GI50=3.2 μM	22435669
786-0		Growth Inhibition Assay		IC50=4.78773 μM	SANGER
8305C		Growth Inhibition Assay		IC50=2.86645 μM	SANGER
8505C		Growth Inhibition Assay		IC50=1.02331 μM	SANGER
8-MG-BA		Growth Inhibition Assay		IC50=2.33906 μM	SANGER
A101D		Growth Inhibition Assay		IC50=2.20303 μM	SANGER
A172		Growth Inhibition Assay		IC50=7.86172 μM	SANGER
A20		Kinase Assay	1 h	anti-HDAC1 activity with IC50 of 0.112 μM	11960489
A204		Growth Inhibition Assay		IC50=4.35803 μM	SANGER
A2058		Growth Inhibition Assay		IC50=5.05908 μM	SANGER
A2780		Growth Inhibition Assay	96 h	IC50=1.62 μM	21634430
A2780		Growth Inhibition Assay		IC50=4.05966 μM	SANGER
A2780 CisR		Kinase Assay	18 h	Inhibition of HDAC with IC50 of 0.44 μM	23252603
A375		Growth Inhibition Assay		IC50=10.2452 μM	SANGER
A388		Growth Inhibition Assay		IC50=19.0303 μM	SANGER
A3-KAW		Growth Inhibition Assay		IC50=400.59 nM	SANGER
A427		Growth Inhibition Assay		IC50=920.84 nM	SANGER
A431		Cytotoxic Assay	72 h	IC50=4.2 μM	17691763
A431		Cytotoxic Assay	72 h	Cytotoxicity against human A431 cells overexpressing EGFR with IC50 of 4.2 μM	21080629
A431		Growth Inhibition Assay		IC50=2.56335 μM	SANGER
A498	6.2 μM	Growth Inhibition Assay	72 h	GI50=1.6 μM	22435669
A498		Growth Inhibition Assay		IC50=3.20871 μM	SANGER
A4-Fuk		Growth Inhibition Assay		IC50=644.91 nM	SANGER
A549	5 μM	Function Assay	3 h	Induction of autophagy in human A549 cells assessed as increase in LC3II	20855208
A549		Cytotoxic Assay	72 h	Cytotoxicity against human A549 cells overexpressing HDAC with IC50 of 1.8 μM	21080629
A549		Growth Inhibition Assay		IC50=1.079 μM	23644210
A549	5 μM	Function Assay	3 h	does not induce autophagy assessed as increase in LC3II	20855208
A549		Growth Inhibition Assay		IC50=2.44893 μM	SANGER
A549/ATCC	6.2 μM	Growth Inhibition Assay	72 h	GI50=1.6 μM	22435669
A673		Growth Inhibition Assay		IC50=2.25862 μM	SANGER
A704		Growth Inhibition Assay		IC50=5.0306 μM	SANGER
ABC-1		Growth Inhibition Assay		IC50=2.6046 μM	SANGER
ACHN		Growth Inhibition Assay	21 h	GI50=0.65 μM	17662606
ACHN	6.2 μM	Growth Inhibition Assay	72 h	GI50=1.3 μM	22435669
ACHN		Growth Inhibition Assay		IC50=9.24975 μM	SANGER
ACN		Growth Inhibition Assay		IC50=10.8679 μM	SANGER
ALL-PO		Growth Inhibition Assay		IC50=814.66 nM	SANGER
AM-38		Growth Inhibition Assay		IC50=2.77355 μM	SANGER
AN3-CA		Growth Inhibition Assay		IC50=6.03441 μM	SANGER
ARP1	2 μM	Function Assay	6 h	Induction of P21WAF1 gene expression	14734806
AsPC1	30 μM	Growth Inhibition Assay	48 h	IC50=3.66 μM	24185378
AsPC-1		Growth Inhibition Assay		IC50=2.7117 μM	SANGER
ATN-1		Growth Inhibition Assay		IC50=740.28 nM	SANGER
AU565		Growth Inhibition Assay		IC50=5.09702 μM	SANGER
BB30-HNC		Growth Inhibition Assay		IC50=10.8711 μM	SANGER
BB49-HNC		Growth Inhibition Assay		IC50=12.3956 μM	SANGER
BB65-RCC		Growth Inhibition Assay		IC50=3.03314 μM	SANGER
BCPAP		Growth Inhibition Assay		IC50=501.42 nM	SANGER
BE(2)-C		Growth Inhibition Assay	72 h	IC70=2 μM	22932316
BE-13		Growth Inhibition Assay		IC50=526.96 nM	SANGER
Becker		Growth Inhibition Assay		IC50=3.75012 μM	SANGER
Bel7402		Growth Inhibition Assay	72 h	GI90=17 μM	23061376
Bel7404		Growth Inhibition Assay	72 h	GI90=18 μM	23061376
BEN		Growth Inhibition Assay		IC50=9.82159 μM	SANGER
BFTC-905		Growth Inhibition Assay		IC50=2.85523 μM	SANGER
BFTC-909		Growth Inhibition Assay		IC50=7.00641 μM	SANGER
BGC823		Growth Inhibition Assay	72 h	GI90=7.5 μM	23061376
BGC823		Growth Inhibition Assay		GI50=3.09 μM	23601706
BHK	5 μM	Kinase Assay	24 h	Inhibition of HDAC7 expressed assessed as increase in plasma membrane Fdelta508 CFTR protein	19966789
BHT-101		Growth Inhibition Assay		IC50=244.18 nM	SANGER
BHY		Growth Inhibition Assay		IC50=4.12495 μM	SANGER
BJ	100 μM	Growth Inhibition Assay	48 h	Growth inhibition at 0.05 to 100 uM	20143840
BPH-1		Growth Inhibition Assay		IC50=2.6585 μM	SANGER
BT-20		Growth Inhibition Assay		IC50=4.79429 μM	SANGER
BT-474		Growth Inhibition Assay		IC50=3.6331 μM	SANGER
BT549	6.2 μM	Growth Inhibition Assay	72 h	GI50=1.3 μM	22435669
BV-173		Growth Inhibition Assay		IC50=1.47291 μM	SANGER
BxPC3		Growth Inhibition Assay	72 h	IC50=2.7 μM	20143778
BxPC-3		Growth Inhibition Assay		IC50=11.3747 μM	SANGER
C2BBe1		Growth Inhibition Assay		IC50=472.19 nM	SANGER
C32		Growth Inhibition Assay		IC50=6.13034 μM	SANGER
C-33-A		Growth Inhibition Assay		IC50=45.3256 μM	SANGER
C3A		Growth Inhibition Assay		IC50=7.3452 μM	SANGER
C8166		Growth Inhibition Assay		IC50=2.21334 μM	SANGER
Ca9-22		Growth Inhibition Assay		IC50=1.05107 μM	SANGER
Caco-2	100 μM	Growth Inhibition Assay	48h	IC50=8.1 μM	20143840
Caco-2	5 μM	Kinase Assay	4 h	Induction of HDAC-mediated histone acetylation IC50 of 0.037 μM	20143840
Caco-2	0.316 nM to 31.6 μM	Kinase Assay	4 h	Ex vivo inhibition of human HDAC1 with IC50 of 0.119 μM	20143840
Caco-2	0.316 nM to 31.6 μM	Kinase Assay	4 h	Ex vivo inhibition of human HDAC3 with IC50 of 0.147 μM	20143840
Caco-2	6.32 nM to 632 μM	Kinase Assay	4 h	Ex vivo inhibition of human HDAC5 with IC50 of 12.6 μM	20143840
Caco-2	6.32 nM to 632 μM	Kinase Assay	4 h	Ex vivo inhibition of human HDAC7 with IC50 of 41 μM	20143840
Caco-2	0.316 nM to 31.6 μM	Kinase Assay	4 h	Ex vivo inhibition of human HDAC6	20143840
Caco-2	5 μM	Function Assay	24 h	does not induce P21WAF1 gene expression	20143840
CAKI-1		Growth Inhibition Assay		IC50=3.89052 μM	SANGER
CAL-120		Growth Inhibition Assay		IC50=4.38992 μM	SANGER
CAL-12T		Growth Inhibition Assay		IC50=4.13103 μM	SANGER
Cal27		Cytotoxic Assay	72 h	IC50=3.2 μM	17691763
CAL27		Growth Inhibition Assay	72 h	IC50=3.72 μM	20143778
CAL27		Cytotoxic Assay	72 h	Cytotoxicity against human CAL27 cells overexpressing EGFR with IC50 of 3.2 μM	21080629
CAL-27		Growth Inhibition Assay		IC50=1.70621 μM	SANGER
CAL27 CisR		Kinase Assay	18 h	Inhibition of HDAC with IC50 of 0.61 μM	23252603
CAL27 sens		Kinase Assay	18 h	Inhibition of HDAC with IC50 of 0.36 μM	23252603
CAL-33		Growth Inhibition Assay		IC50=4.23064 μM	SANGER
CAL-39		Growth Inhibition Assay		IC50=2.23626 μM	SANGER
CAL-51		Growth Inhibition Assay		IC50=2.16699 μM	SANGER
CAL-54		Growth Inhibition Assay		IC50=4.22381 μM	SANGER
CAL-62		Growth Inhibition Assay		IC50=3.54514 μM	SANGER
CAL-85-1		Growth Inhibition Assay		IC50=13.4399 μM	SANGER
Calu-3		Growth Inhibition Assay		IC50=5.06452 μM	SANGER
Calu-6		Growth Inhibition Assay		IC50=9.37528 μM	SANGER
CAMA-1		Growth Inhibition Assay		IC50=1.71971 μM	SANGER
Capan1		Growth Inhibition Assay	72 h	IC50=7.3 μM	20143778
CAPAN-1		Growth Inhibition Assay		IC50=4.42382 μM	SANGER
CaR-1		Growth Inhibition Assay		IC50=2.86 μM	SANGER
CAS-1		Growth Inhibition Assay		IC50=11.4109 μM	SANGER
Ca-Ski		Growth Inhibition Assay		IC50=3.4543 μM	SANGER
CCD1059SK		Growth Inhibition Assay		IC50=43.5 μM	18247554
CCRF-CEM		Cytotoxic Assay	72 h	IC50=0.8 μM	17691763
CCRF-CEM		Growth Inhibition Assay		IC50=2.53043 μM	SANGER
CEM		Kinase Assay	1 h	Inhibition of HDAC with IC50 of 0.33 μM	16420064
CFBE41o	5 μM	Kinase Assay		Down regulation of HDAC7 at 0.2 to 5 uM	21984958
CFBE41o	1 μM	Function Assay	24 h	Restoration of CFTR deltaF508 mutant trafficking to cell surface as glycoforms	21984958
CFBE41o-	5 μM	Kinase Assay	8 h	Inhibition of HDAC assessed as hyperacetylation of histone H3	19966789
CFBE41o-	5 μM	Kinase Assay	4 h	Inhibition of HDAC assessed as increase in mutant Fdelta508 CFTR protein level	19966789
CFBE41o-	1 μM	Kinase Assay	1 h	Inhibition of HDAC assessed as increase in CFTR protein level	19966789
CFBE41o-	1 μM	Kinase Assay	5 days	Inhibition of HDAC7 assessed as increase in stabilization of Fdelta508 CFTR protein	19966789
CFBE41o-	1 μM	Kinase Assay	24 h	Inhibition of HDAC7 assessed as increase in Fdelta508 CFTR protein trafficking	19966789
CFBE41o-	5 μM	Kinase Assay	24 h	Inhibition of HDAC7 assessed as increase in rate of maturation of CFTR protein to its glycoform	19966789
CFBE41o-	5 μM	Kinase Assay	24 h	Inhibition of HDAC7 assessed as increase in stability of Fdelta508 CFTR protein	19966789
CFBE41o-	5 μM	Kinase Assay	24 h	Inhibition of HDAC7 assessed as correction of mutant Fdelta508 CFTR trafficking to cell surface as glycoform	19966789
CFPAC-1		Growth Inhibition Assay		IC50=7.36222 μM	SANGER
CGTH-W-1		Growth Inhibition Assay		IC50=1.89946 μM	SANGER
ChaGo-K-1		Growth Inhibition Assay		IC50=15.8359 μM	SANGER
CHL-1		Growth Inhibition Assay		IC50=642.08 nM	SANGER
CHP-212		Growth Inhibition Assay		IC50=457.53 nM	SANGER
COLO205	10 μM	Kinase Assay	24 h	Inhibition of HDAC1 assessed as induction of histone H3 acetylation with IC50 of 2.2 μM	20451378
COLO205		Growth Inhibition Assay	96 h	IC50=2.12 μM	21634430
COLO-320-HSR		Growth Inhibition Assay		IC50=1.88197 μM	SANGER
COLO-668		Growth Inhibition Assay		IC50=5.7132 μM	SANGER
COLO-678		Growth Inhibition Assay		IC50=27.4919 μM	SANGER
COLO-679		Growth Inhibition Assay		IC50=6.00255 μM	SANGER
COLO-680N		Growth Inhibition Assay		IC50=7.9173 μM	SANGER
COLO-684		Growth Inhibition Assay		IC50=1.46118 μM	SANGER
COLO-741		Growth Inhibition Assay		IC50=4.55994 μM	SANGER
COLO-792		Growth Inhibition Assay		IC50=5.26356 μM	SANGER
COLO-800		Growth Inhibition Assay		IC50=1.71179 μM	SANGER
COLO-824		Growth Inhibition Assay		IC50=7.72863 μM	SANGER
COLO-829		Growth Inhibition Assay		IC50=3.50073 μM	SANGER
COR-L105		Growth Inhibition Assay		IC50=4.13051 μM	SANGER
COR-L23	10 μM	Growth Inhibition Assay	72 h	GI50=1.1 μM	21080647
COR-L23		Growth Inhibition Assay		IC50=2.58566 μM	SANGER
COR-L88		Growth Inhibition Assay		IC50=1.56424 μM	SANGER
CP50-MEL-B		Growth Inhibition Assay		IC50=9.92432 μM	SANGER
CTB-1		Growth Inhibition Assay		IC50=537.92 nM	SANGER
CTV-1		Growth Inhibition Assay		IC50=581.56 nM	SANGER
CW-2		Growth Inhibition Assay		IC50=4.19001 μM	SANGER
D-247MG		Growth Inhibition Assay		IC50=11.1009 μM	SANGER
D-263MG		Growth Inhibition Assay		IC50=3.82051 μM	SANGER
D-283MED		Growth Inhibition Assay		IC50=714.14 nM	SANGER
D-336MG		Growth Inhibition Assay		IC50=41.8442 μM	SANGER
D-392MG		Growth Inhibition Assay		IC50=9.25715 μM	SANGER
D-423MG		Growth Inhibition Assay		IC50=706.89 nM	SANGER
D-502MG		Growth Inhibition Assay		IC50=8.76994 μM	SANGER
D-566MG		Growth Inhibition Assay		IC50=838.62 nM	SANGER
Daoy		Growth Inhibition Assay		IC50=1.76319 μM	SANGER
DB		Growth Inhibition Assay		IC50=598.57 nM	SANGER
DBTRG-05MG		Growth Inhibition Assay		IC50=8.87565 μM	SANGER
DEL		Growth Inhibition Assay		IC50=1.35162 μM	SANGER
Detroit562		Growth Inhibition Assay		IC50=3.65022 μM	SANGER
DJM-1		Growth Inhibition Assay		IC50=3.37674 μM	SANGER
DK-MG		Growth Inhibition Assay		IC50=5.18438 μM	SANGER
DMS114		Growth Inhibition Assay	48 h	GI50=2.9 μM	19419205
DMS-114		Growth Inhibition Assay		IC50=3.47066 μM	SANGER
DMS-273		Growth Inhibition Assay		IC50=2.14837 μM	SANGER
DMS-79		Growth Inhibition Assay		IC50=5.13883 μM	SANGER
DOHH-2		Growth Inhibition Assay		IC50=706.68 nM	SANGER
DOK		Growth Inhibition Assay		IC50=4.26593 μM	SANGER
DoTc2-4510		Growth Inhibition Assay		IC50=2.62185 μM	SANGER
DSH1		Growth Inhibition Assay		IC50=2.16398 μM	SANGER
DU145	10 μM	Growth Inhibition Assay	72 h	GI50=1.05 μM	21080647
DU145	2.5 μM	Kinase Assay	24 h	Inhibition of HDAC assessed as upregulation of p21waf1 protein expression	22260166
DU145	5 μM	Kinase Assay	24 h	Inhibition of HDAC assessed as histone H4 acetylation	22260166
DU145	5 μM	Kinase Assay	24 h	Inhibition of HDAC assessed as histone H3 hyperacetylation	22260166
DU-4475		Growth Inhibition Assay		IC50=751.91 nM	SANGER
ECC10		Growth Inhibition Assay		IC50=945.87 nM	SANGER
EC-GI-10		Growth Inhibition Assay		IC50=3.26153 μM	SANGER
EFM-19		Growth Inhibition Assay		IC50=1.04879 μM	SANGER
EFO-27		Growth Inhibition Assay		IC50=1.25043 μM	SANGER
EGI-1		Growth Inhibition Assay		IC50=2.81743 μM	SANGER
EKVX	6.2 μM	Growth Inhibition Assay	72 h	GI50=1.3 μM	22435669
EKVX		Growth Inhibition Assay		IC50=7.19267 μM	SANGER
EM-2		Growth Inhibition Assay		IC50=1.70014 μM	SANGER
EOL1		Cytotoxic Assay	72 h	IC50=1 μM	17691763
EoL-1-cell		Growth Inhibition Assay		IC50=45425 nM	SANGER
EPLC-272H		Growth Inhibition Assay		IC50=4.3895 μM	SANGER
ES1		Growth Inhibition Assay		IC50=724.4 nM	SANGER
ES2		Growth Inhibition Assay	48 h	IC50=12.7 μM	23493449
ES3		Growth Inhibition Assay		IC50=1.82681 μM	SANGER
ES4		Growth Inhibition Assay		IC50=1.78741 μM	SANGER
ES5		Growth Inhibition Assay		IC50=1.443 μM	SANGER
ES6		Growth Inhibition Assay		IC50=1.93631 μM	SANGER
ES7		Growth Inhibition Assay		IC50=1.54773 μM	SANGER
ES8		Growth Inhibition Assay		IC50=523.53 nM	SANGER
ESS-1		Growth Inhibition Assay		IC50=4.42724 μM	SANGER
ETK-1		Growth Inhibition Assay		IC50=3.94635 μM	SANGER
EW-1		Growth Inhibition Assay		IC50=947.26 nM	SANGER
EW-11		Growth Inhibition Assay		IC50=1.36026 μM	SANGER
EW-13		Growth Inhibition Assay		IC50=3.5251 μM	SANGER
EW-16		Growth Inhibition Assay		IC50=1.74107 μM	SANGER
EW-18		Growth Inhibition Assay		IC50=832.96 nM	SANGER
EW-22		Growth Inhibition Assay		IC50=1.92887 μM	SANGER
EW-24		Growth Inhibition Assay		IC50=1.46531 μM	SANGER
EW-3		Growth Inhibition Assay		IC50=1.17212 μM	SANGER
FADU		Growth Inhibition Assay		IC50=2.47162 μM	SANGER
Friend leukemic cell	50 μM	Growth Inhibition Assay	72 h	IC50=0.99 μM	12109913
FTC-133		Growth Inhibition Assay		IC50=4.79263 μM	SANGER
G401		Growth Inhibition Assay	72 h	IC50=1 μM	18370373
G-401		Growth Inhibition Assay		IC50=3.79085 μM	SANGER
G-402		Growth Inhibition Assay		IC50=2.70451 μM	SANGER
GAK		Growth Inhibition Assay		IC50=32.2616 μM	SANGER
GAMG		Growth Inhibition Assay		IC50=2.44561 μM	SANGER
GB-1		Growth Inhibition Assay		IC50=2.32335 μM	SANGER
GBC-SD	5 μM	Growth Inhibition Assay	72 h	IC50=14.8 μM	23707260
GCIY		Growth Inhibition Assay		IC50=4.77424 μM	SANGER
GCT		Growth Inhibition Assay		IC50=2.1777 μM	SANGER
GI-1		Growth Inhibition Assay		IC50=2.30543 μM	SANGER
GI-ME-N		Growth Inhibition Assay		IC50=3.29511 μM	SANGER
GM11272	100 nM	Function Assay	72 h	Reactivation of MeCp2 mutant expression at 10 to 100 nM	21840716
GM11272	0.1 μM	Function Assay	72 h	does not reactivate MeCp2 mutant expression	21840716
GM15850	2.5 μM	Kinase Assay	96 h	Inhibition of HDAC assessed as increase in histone H3 lysine 14 acetylation of FXN gene	16921367
GM15850	2.5 μM	Kinase Assay	96 h	Inhibition of HDAC assessed as increase in histone H4 lysine 5 acetylation of FXN gene	16921367
GM15850	2.5 μM	Kinase Assay	96 h	Inhibition of HDAC assessed as increase in histone H4 lysine 12 acetylation of FXN gene	16921367
GM15850	2.5 μM	Kinase Assay	96 h	Inhibition of HDAC assessed as increase in histone H3 lysine 9 acetylation of FXN gene	16921367
GM15850	2.5 μM	Kinase Assay	96 h	Inhibition of HDAC assessed as increase in histone H4 lysine 8 acetylation of FXN gene	16921367
GM15850	2.5 μM	Kinase Assay	96 h	Inhibition of HDAC assessed as increase in histone H4 lysine 16 acetylation of FXN gene	16921367
GM15850	2.5 μM	Kinase Assay	96 h	does not inhibit HDAC assessed as increase in histone H3 lysine 14 acetylation of FXN gene	16921367
GM15850	2.5 μM	Kinase Assay	96 h	does not inhibit HDAC assessed as increase in histone H4 lysine 5 acetylation of FXN gene	16921367
GM15850	2.5 μM	Kinase Assay	96 h	does not inhibit HDAC assessed as increase in histone H4 lysine 12 acetylation of FXN gene	16921367
GM15850	2.5 μM	Kinase Assay	96 h	does not inhibit HDAC assessed as increase in histone H3 lysine 9 acetylation of FXN gene	16921367
GM15850	2.5 μM	Kinase Assay	96 h	does not inhibit HDAC assessed as increase in histone H4 lysine 8 acetylation of FXN gene	16921367
GM15850	2.5 μM	Kinase Assay	96 h	does not inhibit HDAC assessed as increase in histone H4 lysine 16 acetylation of FXN gene	16921367
GM15850	5 μM	Function Assay	12 h	has no effect on FXN mRNA expression	16921367
GMS-10		Growth Inhibition Assay		IC50=4.42819 μM	SANGER
GOTO		Growth Inhibition Assay		IC50=729.12 nM	SANGER
GP5d		Growth Inhibition Assay		IC50=3.7295 μM	SANGER
GR-ST		Growth Inhibition Assay		IC50=3.22139 μM	SANGER
GT3TKB		Growth Inhibition Assay		IC50=3.11283 μM	SANGER
H1299		Kinase Assay	20 min	Inhibitory activity against HDAC enzyme with IC50 of 0.194 μM	14521422
H1299		Growth Inhibition Assay	72 h	IC50=7.24 μM	14521422
H4		Growth Inhibition Assay		IC50=1.50912 μM	SANGER
H460		Cytotoxic Assay	12 h	IC50=0.82 μM	24766560
H661		Growth Inhibition Assay	48 h	IC50=1 μM	17157009
H9		Growth Inhibition Assay		IC50=255.04 nM	SANGER
HAL-01		Growth Inhibition Assay		IC50=968.04 nM	SANGER
HBC5		Growth Inhibition Assay	48 h	GI50=17 μM	19419205
HC-1		Growth Inhibition Assay		IC50=1.59866 μM	SANGER
HCC1395		Growth Inhibition Assay		IC50=8.05452 μM	SANGER
HCC1419		Growth Inhibition Assay		IC50=1.34027 μM	SANGER
HCC1569		Growth Inhibition Assay		IC50=4.88458 μM	SANGER
HCC1806		Growth Inhibition Assay		IC50=4.20312 μM	SANGER
HCC1937		Growth Inhibition Assay		IC50=47.1958 μM	SANGER
HCC1954		Growth Inhibition Assay		IC50=31.3666 μM	SANGER
HCC2218		Growth Inhibition Assay		IC50=958.48 nM	SANGER
HCC2998		Growth Inhibition Assay		IC50=9.13681 μM	SANGER
HCC38		Growth Inhibition Assay		IC50=10.322 μM	SANGER
HCC70		Growth Inhibition Assay		IC50=14.4233 μM	SANGER
HCC827		Growth Inhibition Assay	72 h	IC50=1.8 μM	20143778
HCE-4		Growth Inhibition Assay		IC50=3.91663 μM	SANGER
HCE-T		Growth Inhibition Assay		IC50=1.715 μM	SANGER
HCT116		Growth Inhibition Assay	72h	IC50=0.31 μM	19084294
HCT116	30 μM	Kinase Assay	30 h	Inhibition of HDAC6 assessed as induction of alpha-tubulin acetylation	21080647
HCT116	30 μM	Kinase Assay	30 h	Inhibition of HDAC1 assessed as induction of histone H3K9 acetylation	21080647
HCT116		Growth Inhibition Assay		IC50=0.757 μM	23644210
HCT116	0.3 μM	Kinase Assay	30 h	does not inhibit HDAC1 assessed as induction of histone H3K9 acetylation	21080647
HCT116	3 μM	Apoptosis Assay	24 h	does not induce apoptosis assessed as increase in p53 protein level	24766560
HCT-116		Growth Inhibition Assay		IC50=1.1775 μM	SANGER
HCT15		Growth Inhibition Assay	48 h	GI50=0.82 μM	16723227
HCT15	6.2 μM	Growth Inhibition Assay	72 h	GI50=2.5 μM	22435669
HDLM-2		Growth Inhibition Assay		IC50=47.2287 μM	SANGER
HD-MY-Z		Growth Inhibition Assay		IC50=538.13 nM	SANGER
HEC-1		Growth Inhibition Assay		IC50=1.9536 μM	SANGER
Hec-1-A		Cytotoxic Assay	72 h	IC50=1 μM	17691763
HEK293		Kinase Assay	1 h	Inhibition of HDAC1 with IC50 of 0.03 μM	18308563
HEK293		Kinase Assay	1 h	Inhibition of HDAC3 with IC50 of 0.057 μM	18308563
HEK293		Kinase Assay	3 h	Inhibition of recombinant HDAC6 expression with IC50 of 0.019 μM	18558669
HEK293	10 μM	Function Assay	24 h	Activation of mouse Wnt3a signaling expressed	19022675
HEK293		Growth Inhibition Assay	72 h	GI50=13 μM	24900500
HEK-TE	5 μM	Function Assay	6h	Increase in histone H3 acetylation	18434144
HEL		Growth Inhibition Assay	48 h	IC50=0.49 μM	24694055
HEL		Growth Inhibition Assay		IC50=806.08 nM	SANGER
HeLa		Kinase Assay	30 min	Inhibitory concentration against histone deacetylase with IC50 of 0.28 μM	15603949
HeLa	10 μM	Kinase Assay	30 min	Inhibition of recombinant HDAC1 with IC50 of 0.02 μM	17691763
HeLa		Growth Inhibition Assay	72 h	IC50=0.46 μM	18370373
HeLa		Kinase Assay	2 h	Inhibition of nuclear HDAC with IC50 of 0.083 μM	18558669
HeLa	2 μM	Kinase Assay	30 min	Inhibition of HDAC2 in human HeLa cells with IC50 of 0.1 μM	19084294
HeLa		Kinase Assay	15 min	Inhibition of HDAC6 from nuclear extract with IC50 of 0.0855 μM	19093884
HeLa		Kinase Assay	15 min	Inhibition of HDAC8 from nuclear extract with IC50 of 1.86 μM	19093884
HeLa		Growth Inhibition Assay	72 h	IC50=0.46 μM	19441846
HeLa		Cytotoxic Assay	72 h	Cytotoxicity against human HeLa cells overexpressing HDAC with IC50 of 1.5 μM	21080629
H-EMC-SS		Growth Inhibition Assay		IC50=13.9104 μM	SANGER
Hep3B		Growth Inhibition Assay	48 h	GI50=1.21 μM	21712146
Hep3B		Growth Inhibition Assay	48 h	GI50=0.69 μM	22439863
HepG2		Growth Inhibition Assay		IC50=0.0006 μM	18247554
HepG2	5 μM	Kinase Assay	6h	Induction of HDAC-mediated histone acetylation	20143840
HepG2	5 μM	Kinase Assay	6h	Induction of HDAC-mediated histone hyperacetylation	20143840
HepG2	5 μM	Kinase Assay	6h	Induction of HDAC-mediated alpha-tubulin acetylation	20143840
HepG2	5 μM	Kinase Assay	6h	Induction of HDAC-mediated H3/H4 histone acetylation	20143840
HepG2	10 μM	Function Assay	24 h	does not induce apoptosis assessed as hyperacetylation of p53	21548582
HGC27	5 μM	Growth Inhibition Assay	72 h	IC50=5.4 μM	23707260
HGC-27		Growth Inhibition Assay		IC50=872.34 nM	SANGER
HH		Growth Inhibition Assay		IC50=894.12 nM	SANGER
High5		Kinase Assay	24 h	Inhibition of human recombinant HDAC6 with IC50 of 0.09 μM	23602523
High5		Kinase Assay	24 h	Inhibition of human recombinant HDAC1 with IC50 of 0.12 μM	23602523
High5		Kinase Assay	24 h	Inhibition of human recombinant HDAC3 with IC50 of 0.17 μM	23602523
HL60	5 μM	Kinase Assay	24 h	Inhibition of HDAC	23707260
HL60		Growth Inhibition Assay	72 h	GI50=0.93 μM	24900500
HL-60		Growth Inhibition Assay		IC50=1.93902 μM	SANGER
HLE		Growth Inhibition Assay		IC50=2.08529 μM	SANGER
HMV-II		Growth Inhibition Assay		IC50=4.5173 μM	SANGER
HN		Growth Inhibition Assay		IC50=1.88725 μM	SANGER
HO-1-N-1		Growth Inhibition Assay		IC50=1.23835 μM	SANGER
HOP92	6.2 μM	Growth Inhibition Assay	72 h	GI50=4 μM	22435669
HOS		Growth Inhibition Assay		IC50=2.07653 μM	SANGER
HPAF-II		Growth Inhibition Assay		IC50=6.3548 μM	SANGER
HPDE6c7	50 μM	Cytotoxic Assay	72 h	IC50=1.3 μM	18494463
Hs578T		Cytotoxic Assay	48 h	GI=4.83 μM	24015327
Hs-578-T		Growth Inhibition Assay		IC50=4.77655 μM	SANGER
HS68	10 μM	Cytotoxic Assay	72 h	IC50=4.6 μM	23570542
HSC-2		Growth Inhibition Assay		IC50=2.12898 μM	SANGER
HSC3		Cytotoxic Assay	12 h	IC50=0.71 μM	24766560
HSC-3		Growth Inhibition Assay		IC50=2.44509 μM	SANGER
HSC-4		Growth Inhibition Assay		IC50=846.51 nM	SANGER
HT		Growth Inhibition Assay		IC50=1.88947 μM	SANGER
HT1080		Growth Inhibition Assay	72 h	IC50=2.4 μM	12270175
HT1080		Growth Inhibition Assay		IC50=0.0024 μM	18247554
HT-1080		Growth Inhibition Assay		IC50=2.44864 μM	SANGER
HT-1197		Growth Inhibition Assay		IC50=19.9227 μM	SANGER
HT-1376		Growth Inhibition Assay		IC50=5.78052 μM	SANGER
HT-144		Growth Inhibition Assay		IC50=5.24987 μM	SANGER
HT-29		Cytotoxic Assay	12 h	IC50=0.72 μM	24766560
HT-29		Growth Inhibition Assay		IC50=3.26614 μM	SANGER
HT-3		Growth Inhibition Assay		IC50=2.49535 μM	SANGER
HT55		Growth Inhibition Assay		IC50=1.65131 μM	SANGER
HTC-C3		Growth Inhibition Assay		IC50=2.2685 μM	SANGER
HuCCT1		Growth Inhibition Assay		IC50=5.23856 μM	SANGER
HuH-7		Growth Inhibition Assay		IC50=2.30637 μM	SANGER
human HOP-92		Growth Inhibition Assay		IC50=1.94065 μM	SANGER
Human microvascular epithelial cell	50 μM	Cytotoxic Assay	72 h	IC50=1.3 μM	18494463
Human renal epithelial cell		Growth Inhibition Assay	72 h	IC50=14 μM	18370373
HuO-3N1		Growth Inhibition Assay		IC50=1.59385 μM	SANGER
HuO9		Growth Inhibition Assay		IC50=1.45362 μM	SANGER
Hup T3	50 μM	Cytotoxic Assay	72h	IC50=0.8 μM	18494463
HuP-T3		Growth Inhibition Assay		IC50=5.88677 μM	SANGER
HuP-T4		Growth Inhibition Assay		IC50=1.493 μM	SANGER
HUT78		Growth Inhibition Assay	72 h	GI50=0.3 μM	20884208
IA-LM		Growth Inhibition Assay		IC50=1.69278 μM	SANGER
IGR-1		Growth Inhibition Assay		IC50=20.3117 μM	SANGER
IGROV1		Growth Inhibition Assay	72 h	IC50=2.2 μM	19084294
IGROV1	5 μM	Kinase Assay	24 h	Inhibition of HDAC assessed as p53 acetylation	19084294
IGROV1	10 μM	Kinase Assay	4 h	Inhibition of HDAC assessed as histone-H4 acetylation	19084294
IGROV1	10 μM	Kinase Assay	4 h	Inhibition of HDAC6 assessed as alpha-tubulin acetylation	19084294
IGROV1	6.2 μM	Growth Inhibition Assay	72 h	GI50=1.3 μM	22435669
IST-MEL1		Growth Inhibition Assay		IC50=6.89669 μM	SANGER
IST-MES1		Growth Inhibition Assay		IC50=9.51644 μM	SANGER
IST-SL1		Growth Inhibition Assay		IC50=2.16844 μM	SANGER
J82		Growth Inhibition Assay		IC50=3.5057 μM	SANGER
JAR		Growth Inhibition Assay		IC50=2.31987 μM	SANGER
JEG-3		Growth Inhibition Assay		IC50=8.78618 μM	SANGER
J-RT3-T3-5		Growth Inhibition Assay		IC50=910.49 nM	SANGER
Jurkat	100 μM	Cytotoxic Assay	72 h	GI50=0.9 μM	24900743
Jurkat	20 μM	Cytotoxic Assay	72 h	no cytotoxicity assessed as growth inhibition	24304348
Jurkat E6.1		Kinase Assay	2 h	Inhibition of HDAC4 with IC50 of 0.04 μM	24261862
JVM-3		Growth Inhibition Assay		IC50=1.85451 μM	SANGER
K5		Growth Inhibition Assay		IC50=2.07811 μM	SANGER
K562		Kinase Assay	6 h	Inhibition of human histone deacetylase (mixture of HDAC1 and HDAC2) with IC50 of 0.01 μM	12419380
K562		Growth Inhibition Assay		IC50=0.645 μM	23644210
K562		Kinase Assay		does not inhibit HDAC	23591111
K-562		Growth Inhibition Assay		IC50=18.6317 μM	SANGER
KALS-1		Growth Inhibition Assay		IC50=8.50928 μM	SANGER
KARPAS-45		Growth Inhibition Assay		IC50=173.89 nM	SANGER
KASUMI-1		Growth Inhibition Assay		IC50=99.17 nM	SANGER
KB		Cytotoxic Assay	12 h	IC50=0.75 μM	24766560
KE-37		Growth Inhibition Assay		IC50=894.62 nM	SANGER
KG1		Growth Inhibition Assay	48 h	IC50=1.15 μM	24525003
KG-1		Growth Inhibition Assay		IC50=775.45 nM	SANGER
KGN		Growth Inhibition Assay		IC50=12.2901 μM	SANGER
KINGS-1		Growth Inhibition Assay		IC50=6.26152 μM	SANGER
KLE		Growth Inhibition Assay		IC50=9.32232 μM	SANGER
KM12		Cytotoxic Assay	48 h	GI=1.88 μM	24015327
KM12		Growth Inhibition Assay		IC50=6.24099 μM	SANGER
KM-H2		Growth Inhibition Assay		IC50=3.82624 μM	SANGER
KMOE-2		Growth Inhibition Assay		IC50=1.09422 μM	SANGER
KNS-42		Growth Inhibition Assay		IC50=16.6589 μM	SANGER
KNS-62		Growth Inhibition Assay		IC50=2.45061 μM	SANGER
KNS-81-FD		Growth Inhibition Assay		IC50=14.7045 μM	SANGER
KOSC-2		Growth Inhibition Assay		IC50=2.56076 μM	SANGER
KP-4		Growth Inhibition Assay		IC50=1.37085 μM	SANGER
KP-N-YN		Growth Inhibition Assay		IC50=4.20927 μM	SANGER
KP-N-YS		Growth Inhibition Assay		IC50=2.32615 μM	SANGER
KS-1		Growth Inhibition Assay		IC50=5.98836 μM	SANGER
KU-19-19		Growth Inhibition Assay		IC50=2.53513 μM	SANGER
KU812		Growth Inhibition Assay		IC50=813.1 nM	SANGER
KURAMOCHI		Growth Inhibition Assay		IC50=28.126 μM	SANGER
KY821		Growth Inhibition Assay		IC50=563.25 nM	SANGER
KYSE-140		Growth Inhibition Assay		IC50=7.44061 μM	SANGER
KYSE-150		Growth Inhibition Assay		IC50=11.0387 μM	SANGER
KYSE-180		Growth Inhibition Assay		IC50=3.63372 μM	SANGER
KYSE-270		Growth Inhibition Assay		IC50=5.66031 μM	SANGER
KYSE-410		Growth Inhibition Assay		IC50=6.30645 μM	SANGER
KYSE-450		Growth Inhibition Assay		IC50=3.68582 μM	SANGER
KYSE-510		Growth Inhibition Assay		IC50=3.72181 μM	SANGER
KYSE-510 CisR		Kinase Assay	18 h	Inhibition of HDAC with IC50 of 0.59 μM	23252603
KYSE-510 sens		Kinase Assay	18 h	Inhibition of HDAC with IC50 of 0.7 μM	23252603
KYSE-520		Growth Inhibition Assay		IC50=14.927 μM	SANGER
KYSE-70		Growth Inhibition Assay		IC50=4.2934 μM	SANGER
L-363		Growth Inhibition Assay		IC50=503.1 nM	SANGER
L-428		Growth Inhibition Assay		IC50=3.40045 μM	SANGER
LAMA-84		Growth Inhibition Assay		IC50=1.43945 μM	SANGER
LAN-6		Growth Inhibition Assay		IC50=6.49631 μM	SANGER
LB1047-RCC		Growth Inhibition Assay		IC50=1.18312 μM	SANGER
LB2241-RCC		Growth Inhibition Assay		IC50=1.98231 μM	SANGER
LB2518-MEL		Growth Inhibition Assay		IC50=3.22398 μM	SANGER
LB771-HNC		Growth Inhibition Assay		IC50=14.419 μM	SANGER
LB831-BLC		Growth Inhibition Assay		IC50=9.45171 μM	SANGER
LC-2-ad		Growth Inhibition Assay		IC50=8.21937 μM	SANGER
LCLC-103H		Growth Inhibition Assay		IC50=2.90438 μM	SANGER
LCLC-97TM1		Growth Inhibition Assay		IC50=2.14583 μM	SANGER
LK-2		Growth Inhibition Assay		IC50=10.4208 μM	SANGER
LN-405		Growth Inhibition Assay		IC50=5.73085 μM	SANGER
LNCAP		Growth Inhibition Assay	72 h	IC50=0.58 μM	20143778
LNCaP-Clone-FGC		Growth Inhibition Assay		IC50=6.80403 μM	SANGER
LoVo	10 μM	Growth Inhibition Assay	72 h	GI50=1.7 μM	21080647
LoVo		Growth Inhibition Assay		IC50=1.8981 μM	SANGER
LOXIMVI	6.2 μM	Growth Inhibition Assay	72 h	GI50=1 μM	22435669
LOXIMVI		Growth Inhibition Assay		IC50=1.7211 μM	SANGER
LOX-IMVI		Growth Inhibition Assay	48 h	IC50=1.3 μM	15715470
LS-1034		Growth Inhibition Assay		IC50=8.57437 μM	SANGER
LS-123		Growth Inhibition Assay		IC50=3.87909 μM	SANGER
LS-411N		Growth Inhibition Assay		IC50=2.8233 μM	SANGER
LS-513		Growth Inhibition Assay		IC50=4.42198 μM	SANGER
LU-134-A		Growth Inhibition Assay		IC50=2.47008 μM	SANGER
LU-135		Growth Inhibition Assay		IC50=19.2636 μM	SANGER
LU-139		Growth Inhibition Assay		IC50=822.86 nM	SANGER
LU-65		Growth Inhibition Assay		IC50=4.07633 μM	SANGER
LU-99A		Growth Inhibition Assay		IC50=6.55989 μM	SANGER
LXF-289		Growth Inhibition Assay		IC50=1.3524 μM	SANGER
M059J		Growth Inhibition Assay		IC50=5.2576 μM	SANGER
M14	6.2 μM	Growth Inhibition Assay	72 h	GI50=1.3 μM	22435669
M14		Growth Inhibition Assay		IC50=2.66993 μM	SANGER
MALME-3M	6.2 μM	Growth Inhibition Assay	72 h	GI50=0.32 μM	22435669
MC116		Growth Inhibition Assay		IC50=1.13621 μM	SANGER
MCF10A	6.2 μM	Growth Inhibition Assay	48 h	GI50=9.6 μM	22435669
MCF7	10 μM	Function Assay	8 h	Induction of tubulin hyperacetylation	18269226
MCF7		Growth Inhibition Assay	48 h	GI=0.45 μM	24119555
MCF7		Growth Inhibition Assay		IC50=5.00738 μM	SANGER
MC-IXC		Growth Inhibition Assay		IC50=1.17881 μM	SANGER
MCR5-SV2	10 μM	Growth Inhibition Assay	72 h	GI50=2.1 μM	21080647
MDA-MB-175-VII		Growth Inhibition Assay		IC50=5.64041 μM	SANGER
MDA-MB-231	10 μM	Kinase Assay	30 min	Inhibition of HDAC2a	23493449
MDA-MB-231	1 μM	Kinase Assay	24 h	Inhibition of HDAC6 assessed as acetylation levels of tubulin	23493449
MDA-MB-231		Growth Inhibition Assay	48 h	IC50=0.16 μM	24095016
MDA-MB-231	10 μM	Kinase Assay	5 min	does not inhibit HDAC2a	23493449
MDA-MB-231	1 μM	Kinase Assay	24 h	does not inhibit HDAC6 assessed as acetylation levels of tubulin	23493449
MDA-MB-231		Growth Inhibition Assay		IC50=4.70243 μM	SANGER
MDA-MB-231 CisR		Kinase Assay	18 h	Inhibition of HDAC with IC50 of 0.61 μM	23252603
MDA-MB-231 sens		Kinase Assay	18 h	Inhibition of HDAC with IC50 of 0.61 μM	23252603
MDA-MB-361		Growth Inhibition Assay		IC50=1.73157 μM	SANGER
MDA-MB-415		Growth Inhibition Assay		IC50=5.92139 μM	SANGER
MDA-MB-435	6.2 μM	Growth Inhibition Assay	72 h	GI50=0.5 μM	22435669
MDA-MB-435		Growth Inhibition Assay	48 h	GI=0.88 μM	24119555
MDA-MB-453		Growth Inhibition Assay		IC50=2.24275 μM	SANGER
MDA-MB-468	6.2 μM	Growth Inhibition Assay	72 h	GI50=0.63 μM	22435669
ME-180		Growth Inhibition Assay		IC50=9.06725 μM	SANGER
MEF	10 μM	Cytotoxic Assay	72 h	IC50=4.4 μM	23570542
MEG-01		Growth Inhibition Assay		IC50=3.06164 μM	SANGER
MEL-HO		Growth Inhibition Assay		IC50=1.00582 μM	SANGER
MEL-JUSO		Growth Inhibition Assay		IC50=3.89153 μM	SANGER
Mewo		Growth Inhibition Assay		IC50=4.81747 μM	SANGER
MFE-280		Growth Inhibition Assay		IC50=9.72785 μM	SANGER
MG-63		Growth Inhibition Assay		IC50=7.41849 μM	SANGER
MGC803		Growth Inhibition Assay	72 h	GI90=10.8 μM	23061376
MHH-ES-1		Growth Inhibition Assay		IC50=1.70435 μM	SANGER
MHH-NB-11		Growth Inhibition Assay		IC50=1.28329 μM	SANGER
MHH-PREB-1		Growth Inhibition Assay		IC50=294.53 nM	SANGER
Mia Paca2	50 μM	Cytotoxic Assay	72h	IC50=1.1 μM	18494463
MIA-PaCa-2		Growth Inhibition Assay		IC50=949.12 nM	SANGER
MKN28		Growth Inhibition Assay		IC50=2.59037 μM	SANGER
MKN45		Cytotoxic Assay	12 h	IC50=1.25 μM	24766560
MKN45		Growth Inhibition Assay		IC50=4.57732 μM	SANGER
MKN7		Growth Inhibition Assay		IC50=5.988 μM	SANGER
ML-2		Growth Inhibition Assay		IC50=1.00407 μM	SANGER
MLMA		Growth Inhibition Assay		IC50=2.96717 μM	SANGER
MMAC-SF		Growth Inhibition Assay		IC50=4.26859 μM	SANGER
MN-60		Growth Inhibition Assay		IC50=1.0268 μM	SANGER
MOLT-13		Growth Inhibition Assay		IC50=738.98 nM	SANGER
MOLT-16		Growth Inhibition Assay		IC50=1.29797 μM	SANGER
MOLT4	6.2 μM	Growth Inhibition Assay	72 h	GI50=0.4 μM	22435669
MOLT-4		Growth Inhibition Assay		IC50=787.46 nM	SANGER
MONE1		Cytotoxic Assay	12 h	IC50=1.18 μM	24766560
Mo-T		Growth Inhibition Assay		IC50=2.50927 μM	SANGER
MPP-89		Growth Inhibition Assay		IC50=7.59729 μM	SANGER
MS-1		Growth Inhibition Assay		IC50=1.00617 μM	SANGER
MSTO-211H		Growth Inhibition Assay		IC50=6.72233 μM	SANGER
MUF	100 μM	Growth Inhibition Assay	48 h	Growth inhibition at 0.05 to 100 uM	20143840
MV-4-11		Growth Inhibition Assay		IC50=659.1 nM	SANGER
MZ1-PC		Growth Inhibition Assay		IC50=24.6759 μM	SANGER
MZ2-MEL		Growth Inhibition Assay		IC50=3.47681 μM	SANGER
NB10		Growth Inhibition Assay		IC50=751.92 nM	SANGER
NB12		Growth Inhibition Assay		IC50=2.7171 μM	SANGER
NB13		Growth Inhibition Assay		IC50=1.05501 μM	SANGER
NB14		Growth Inhibition Assay		IC50=696.95 nM	SANGER
NB17		Growth Inhibition Assay		IC50=2.38243 μM	SANGER
NB4			48h	IC50=0.6 μM	18723349
NB4	5 μM	Function Assay	24 h	Cell cycle arrest assessed as increase in accumulation at pre-G1 phase	20491440
NB4	5 μM	Kinase Assay	24 h	Inhibition of HDAC assessed as increase in acetylate tubulin level	20491440
NB4	5 μM	Function Assay	24 h	Induction of p21WAF1/CIP1 expression	20491440
NB4	5 μM	Kinase Assay	24 h	Inhibition of HDAC assessed as increase in histone H3 acetylation	20491440
NB5		Growth Inhibition Assay		IC50=1.19856 μM	SANGER
NB6		Growth Inhibition Assay		IC50=1.91298 μM	SANGER
NB69		Growth Inhibition Assay		IC50=411.71 nM	SANGER
NB7		Growth Inhibition Assay		IC50=345.74 nM	SANGER
NBsusSR		Growth Inhibition Assay		IC50=1.05166 μM	SANGER
NCI60		Cytotoxic Assay	48 h	GI=0.53 μM	24015327
NCI-ADR-RES	6.2 μM	Growth Inhibition Assay	72 h	GI50=0.16 μM	22435669
NCI-H1048		Growth Inhibition Assay		IC50=2.55025 μM	SANGER
NCI-H1092		Growth Inhibition Assay		IC50=1.15406 μM	SANGER
NCI-H1155		Growth Inhibition Assay		IC50=2.36725 μM	SANGER
NCI-H1299		Growth Inhibition Assay		IC50=5.46335 μM	SANGER
NCI-H1304		Growth Inhibition Assay		IC50=20.7501 μM	SANGER
NCI-H1355		Growth Inhibition Assay		IC50=3.00796 μM	SANGER
NCI-H1395		Growth Inhibition Assay		IC50=10.178 μM	SANGER
NCI-H1437		Growth Inhibition Assay		IC50=2.41873 μM	SANGER
NCI-H1563		Growth Inhibition Assay		IC50=3.33018 μM	SANGER
NCI-H1573		Growth Inhibition Assay		IC50=9.10532 μM	SANGER
NCI-H1581		Growth Inhibition Assay		IC50=3.84488 μM	SANGER
NCI-H1623		Growth Inhibition Assay		IC50=7.14072 μM	SANGER
NCI-H1648		Growth Inhibition Assay		IC50=4.72273 μM	SANGER
NCI-H1650		Growth Inhibition Assay		IC50=30.1924 μM	SANGER
NCI-H1651		Growth Inhibition Assay		IC50=3.24644 μM	SANGER
NCI-H1666		Growth Inhibition Assay		IC50=2.28111 μM	SANGER
NCI-H1693		Growth Inhibition Assay		IC50=12.5816 μM	SANGER
NCI-H1703		Growth Inhibition Assay		IC50=5.35826 μM	SANGER
NCI-H1755		Growth Inhibition Assay		IC50=16.573 μM	SANGER
NCI-H1770		Growth Inhibition Assay		IC50=1.48536 μM	SANGER
NCI-H1792		Growth Inhibition Assay		IC50=4.76107 μM	SANGER
NCI-H1838		Growth Inhibition Assay		IC50=8.25781 μM	SANGER
NCI-H2029		Growth Inhibition Assay		IC50=19.6021 μM	SANGER
NCI-H2030		Growth Inhibition Assay		IC50=6.91226 μM	SANGER
NCI-H2052		Growth Inhibition Assay		IC50=10.1882 μM	SANGER
NCI-H2087		Growth Inhibition Assay		IC50=9.67352 μM	SANGER
NCI-H209		Growth Inhibition Assay		IC50=729.9 nM	SANGER
NCI-H2122		Growth Inhibition Assay	72 h	IC50=7.5 μM	20143778
NCI-H2122		Growth Inhibition Assay		IC50=3.41312 μM	SANGER
NCI-H2126		Growth Inhibition Assay		IC50=2.60984 μM	SANGER
NCI-H2170		Growth Inhibition Assay		IC50=2.50549 μM	SANGER
NCI-H2228		Growth Inhibition Assay		IC50=34.3605 μM	SANGER
NCI-H226		Growth Inhibition Assay	48 h	IC50=2.6 μM	15715470
NCI-H226		Growth Inhibition Assay		IC50=17.9345 μM	SANGER
NCI-H2291		Growth Inhibition Assay		IC50=49.8301 μM	SANGER
NCI-H23		Growth Inhibition Assay	48 h	GI50=0.92 μM	16723227
NCI-H23	6.2 μM	Growth Inhibition Assay	72 h	GI50=1 μM	22435669
NCI-H23		Growth Inhibition Assay		IC50=1.54645 μM	SANGER
NCI-H2347		Growth Inhibition Assay		IC50=23.2674 μM	SANGER
NCI-H2405		Growth Inhibition Assay		IC50=12.2036 μM	SANGER
NCI-H2452		Growth Inhibition Assay		IC50=10.16 μM	SANGER
NCI-H28		Growth Inhibition Assay		IC50=8.05963 μM	SANGER
NCI-H292		Growth Inhibition Assay		IC50=2.86596 μM	SANGER
NCI-H322M	6.2 μM	Growth Inhibition Assay	72 h	GI50=0.79 μM	22435669
NCI-H358		Growth Inhibition Assay	72 h	IC50=2.5 μM	20143778
NCI-H441		Growth Inhibition Assay		IC50=16.0039 μM	SANGER
NCI-H446		Growth Inhibition Assay		IC50=2.04599 μM	SANGER
NCI-H460	6.2 μM	Growth Inhibition Assay	72 h	GI50=0.79 μM	22435669
NCI-H510A		Growth Inhibition Assay		IC50=2.64426 μM	SANGER
NCI-H520		Growth Inhibition Assay		IC50=22.7611 μM	SANGER
NCI-H522	6.2 μM	Growth Inhibition Assay	72 h	GI50=0.5 μM	22435669
NCI-H526		Growth Inhibition Assay		IC50=1.08291 μM	SANGER
NCI-H596		Growth Inhibition Assay		IC50=23.9055 μM	SANGER
NCI-H630		Growth Inhibition Assay		IC50=4.78081 μM	SANGER
NCI-H650		Growth Inhibition Assay		IC50=3.64287 μM	SANGER
NCI-H661		Growth Inhibition Assay		IC50=2.64085 μM	SANGER
NCI-H69		Cytotoxic Assay	72 h	IC50=2.06 μM	19093884
NCI-H69		Growth Inhibition Assay		IC50=1.34112 μM	SANGER
NCI-H720		Growth Inhibition Assay		IC50=560.18 nM	SANGER
NCI-H727		Growth Inhibition Assay		IC50=47.2451 μM	SANGER
NCI-H747		Growth Inhibition Assay		IC50=10.8746 μM	SANGER
NCI-H810		Growth Inhibition Assay		IC50=3.04823 μM	SANGER
NCI-H82		Growth Inhibition Assay		IC50=26.4288 μM	SANGER
NCI-N87		Growth Inhibition Assay		IC50=4.50868 μM	SANGER
NCI-SNU-1		Growth Inhibition Assay		IC50=1.02331 μM	SANGER
NCI-SNU-5		Growth Inhibition Assay		IC50=7.02159 μM	SANGER
NEC8		Growth Inhibition Assay		IC50=289.38 nM	SANGER
NH-12		Growth Inhibition Assay		IC50=1.72691 μM	SANGER
NKM-1		Growth Inhibition Assay		IC50=544.27 nM	SANGER
NMC-G1		Growth Inhibition Assay		IC50=37.0529 μM	SANGER
no-10		Growth Inhibition Assay		IC50=12.1217 μM	SANGER
no-11		Growth Inhibition Assay		IC50=9.26028 μM	SANGER
NOMO-1		Growth Inhibition Assay		IC50=2.19317 μM	SANGER
NOS-1		Growth Inhibition Assay		IC50=1.41194 μM	SANGER
NTERA-S-cl-D1		Growth Inhibition Assay		IC50=1.31761 μM	SANGER
NUGC3	5 μM	Growth Inhibition Assay	24 h	GI50=2.79 μM	17904843
NUGC3		Growth Inhibition Assay		GI50=2.94 μM	20850971
NUGC3	10 μM	Growth Inhibition Assay		GI=2.94 μM	23163332
NUGC-3		Growth Inhibition Assay		IC50=4.25505 μM	SANGER
NY		Growth Inhibition Assay		IC50=49.3908 μM	SANGER
OAW-28		Growth Inhibition Assay		IC50=4.58398 μM	SANGER
OAW-42		Growth Inhibition Assay		IC50=2.33416 μM	SANGER
OC-314		Growth Inhibition Assay		IC50=2.23259 μM	SANGER
OCI-AML2		Growth Inhibition Assay		IC50=4.65238 μM	SANGER
OCUB-M		Growth Inhibition Assay		IC50=3.54665 μM	SANGER
OE19		Growth Inhibition Assay		IC50=8.76262 μM	SANGER
OE33		Growth Inhibition Assay		IC50=4.87713 μM	SANGER
OMC-1		Growth Inhibition Assay		IC50=6.85402 μM	SANGER
ONS-76		Growth Inhibition Assay		IC50=1.82897 μM	SANGER
OS-RC-2		Growth Inhibition Assay		IC50=1.87151 μM	SANGER
OVCAR3	6.2 μM	Growth Inhibition Assay	72 h	GI50=1.3 μM	22435669
OVCAR-3		Growth Inhibition Assay		IC50=7.21133 μM	SANGER
OVCAR4	6.2 μM	Growth Inhibition Assay	72 h	GI50=4 μM	22435669
OVCAR-4		Growth Inhibition Assay		IC50=3.92889 μM	SANGER
OVCAR5	6.2 μM	Growth Inhibition Assay	72 h	GI50=0.79 μM	22435669
OVCAR-5		Growth Inhibition Assay		IC50=576.11 nM	SANGER
OVCAR8	6.2 μM	Growth Inhibition Assay	72 h	GI50=0.5 μM	22435669
OVCAR-8		Growth Inhibition Assay		IC50=1.54477 μM	SANGER
P12-ICHIKAWA		Growth Inhibition Assay		IC50=596.51 nM	SANGER
P30-OHK		Growth Inhibition Assay		IC50=835.7 nM	SANGER
PA-1		Growth Inhibition Assay		IC50=286.26 nM	SANGER
Panc 04.03	50 μM	Cytotoxic Assay	72h	IC50=1.2 μM	18494463
PANC-03-27		Growth Inhibition Assay		IC50=4.99962 μM	SANGER
PANC-08-13		Growth Inhibition Assay		IC50=3.79602 μM	SANGER
PANC1	1 μM	Growth Inhibition Assay		IC50=0.45 μM	17588744
PANC1	1 μM	Function Assay	24 h	Increase in p21WAF1/CIP1 gene expression	17588744
PANC1	1 μM	Function Assay	24 h	Increase in p27kip1 gene expression	17588744
PANC1	1 μM	Function Assay	24 h	does not increase in p27kip1 gene expression	17588744
PANC1	1 μM	Function Assay	48 h	does not increase in p27kip1 gene expression	17588744
PANC-10-05		Growth Inhibition Assay		IC50=8.37047 μM	SANGER
PC-14		Growth Inhibition Assay		IC50=2.8051 μM	SANGER
PC3		Growth Inhibition Assay	21 h	GI50=0.71 μM	17662606
PC-3		Growth Inhibition Assay		IC50=3.03874 μM	SANGER
PFSK-1		Growth Inhibition Assay		IC50=1.8037 μM	SANGER
Primary bronchial epithelial cell	1 μM	Kinase Assay	24 h	Inhibition of HDAC7 assessed as induction of mutant Fdelta508 CFTR protein apical surface localization	19966789
Primary bronchial epithelial cell	5 μM	Kinase Assay	24 h	Inhibition of HDAC assessed as induction of mutant Fdelta508 CFTR protein apical surface localization	19966789
Primary bronchial epithelial cell	1 μM	Kinase Assay	96 h	Inhibition of HDAC7 assessed as increase in short circuit currents	19966789
PSN1		Growth Inhibition Assay		IC50=2.28913 μM	SANGER
PT45		Growth Inhibition Assay		IC50=4 μM	17588744
QIMR-WIL		Growth Inhibition Assay		IC50=862.03 nM	SANGER
Ramos-2G6-4C10		Growth Inhibition Assay		IC50=1.99493 μM	SANGER
RAW264.7	10 μM	Function Assay	24h	Inhibition of LPS-stimulated TNFalpha production with IC50 of 0.76 μM	17477518
RAW264.7	10 μM	Function Assay	24h	Inhibition of LPS-stimulated NO production with IC50 of 1.88 μM	17477518
RAW264.7	2 μM	Function Assay	3.5 h	Antimalarial activity against Plasmodium falciparum infected with IC50 of 0.11 μM	18644969
RCC10RGB		Growth Inhibition Assay		IC50=21.2829 μM	SANGER
RCM-1		Growth Inhibition Assay		IC50=1.12102 μM	SANGER
RD		Growth Inhibition Assay		IC50=974.45 nM	SANGER
RERF-LC-MS		Growth Inhibition Assay		IC50=5.06903 μM	SANGER
RH-1		Growth Inhibition Assay		IC50=3.10278 μM	SANGER
RH-18		Growth Inhibition Assay		IC50=2.35022 μM	SANGER
RKO		Growth Inhibition Assay		IC50=3.30757 μM	SANGER
RKOp21		Cytotoxic Assay	72 h	IC50=1.76 μM	17691763
RMG-I		Growth Inhibition Assay		IC50=3.02592 μM	SANGER
RO82-W-1		Growth Inhibition Assay		IC50=13.0649 μM	SANGER
RPMI-2650		Growth Inhibition Assay		IC50=2.64143 μM	SANGER
RPMI-7951		Growth Inhibition Assay		IC50=3.74723 μM	SANGER
RPMI-8226		Growth Inhibition Assay		IC50=678.18 nM	SANGER
RPMI-8866		Growth Inhibition Assay		IC50=813.67 nM	SANGER
RS4-11		Growth Inhibition Assay		IC50=832.45 nM	SANGER
RT-112		Growth Inhibition Assay		IC50=1.59284 μM	SANGER
RVH-421		Growth Inhibition Assay		IC50=5.49908 μM	SANGER
RXF393	6.2 μM	Growth Inhibition Assay	72 h	GI50=1.3 μM	22435669
RXF393		Growth Inhibition Assay		IC50=3.53294 μM	SANGER
RXF-631L		Growth Inhibition Assay	48 h	IC50=2 μM	15715470
S-117		Growth Inhibition Assay		IC50=8.25353 μM	SANGER
S2	0.1-10 μM	Kinase Assay	1 h	Inhibition of Plasmodium falciparum HDAC1 expressed with IC50 of 0.059 μM	19317450
Saos2		Cytotoxic Assay	72 h	IC50=2.3 μM	17691763
Saos-2		Growth Inhibition Assay		IC50=9.52195 μM	SANGER
SAS		Growth Inhibition Assay		IC50=1.04081 μM	SANGER
SBC-1		Growth Inhibition Assay		IC50=793.84 nM	SANGER
SBC-5		Growth Inhibition Assay		IC50=2.06147 μM	SANGER
SC9		Growth Inhibition Assay	48 h	IC50=0.606 μM	17507219
SCC15		Growth Inhibition Assay	72 h	IC50=2.49 μM	20143778
SCC-15		Growth Inhibition Assay		IC50=1.93819 μM	SANGER
SCC25		Growth Inhibition Assay	72 h	IC50=1.93 μM	20143778
SCC-25		Growth Inhibition Assay		IC50=4.35819 μM	SANGER
SCC4	1 μM	Kinase Assay	24h	Inhibition of HDAC assessed as increase in tubulin acetylation	20452225
SCC4	1 μM	Kinase Assay	24h	Inhibition of HDAC assessed as increase in histone acetylation	20452225
SCC4	1 μM	Function Assay	5 min	Agonist activity at VDR assessed as induction of CYP24 gene expression	20452225
SCC4	1 μM	Function Assay	10 min	has no agonist activity at VDR assessed as induction of CYP24 gene expression	20452225
SCC-4		Growth Inhibition Assay		IC50=2.63012 μM	SANGER
SCC-9		Growth Inhibition Assay		IC50=9.71816 μM	SANGER
SCH		Growth Inhibition Assay		IC50=4.15743 μM	SANGER
SF126		Growth Inhibition Assay		IC50=10.4727 μM	SANGER
Sf21		Kinase Assay	3 h	Inhibition of Flag tagged human recombinant HDAC8 expressed with IC50 of 1.2 μM	21080629
SF268	6.2 μM	Growth Inhibition Assay	72 h	GI50=1.6 μM	22435669
SF268		Growth Inhibition Assay		IC50=3.04523 μM	SANGER
SF295	6.2 μM	Growth Inhibition Assay	72 h	GI50=1.6 μM	22435669
SF295		Growth Inhibition Assay		IC50=1.06624 μM	SANGER
SF539	6.2 μM	Growth Inhibition Assay	72 h	GI50=2 μM	22435669
SF539		Growth Inhibition Assay		IC50=5.26632 μM	SANGER
SGC7901		Growth Inhibition Assay	72 h	GI90=9.4 μM	23061376
SH-4		Growth Inhibition Assay		IC50=9.49364 μM	SANGER
SHP-77		Growth Inhibition Assay		IC50=7.13952 μM	SANGER
SHSY5Y	10 μM	Kinase Assay	48 h	Inhibition of HDAC with IC50 of 0.5 μM	19344175
SHSY5Y	10 μM	Cytotoxic Assay	48 h	IC50=2 μM	19344175
SiHa		Growth Inhibition Assay		IC50=7.83707 μM	SANGER
SJSA-1		Growth Inhibition Assay		IC50=6.56347 μM	SANGER
SKBR3		Growth Inhibition Assay		IC50=0.8 μM	18247554
SKBR3		Cytotoxic Assay	72 h	Cytotoxicity against human SKBR3 cells overexpressing HER2 with IC50 of 2.6 μM	21080629
SKG-IIIa		Growth Inhibition Assay		IC50=1.23464 μM	SANGER
SKHEP1		Growth Inhibition Assay	72 h	IC50=3.46 μM	20143778
SKHEP1		Growth Inhibition Assay	72 h	GI90=17 μM	23061376
SK-HEP-1		Growth Inhibition Assay		IC50=2.74391 μM	SANGER
SK-LU-1		Growth Inhibition Assay		IC50=23.0718 μM	SANGER
SK-MEL-1		Growth Inhibition Assay		IC50=10.7838 μM	SANGER
SK-MEL-2	6.2 μM	Growth Inhibition Assay	72 h	GI50=1.3 μM	22435669
SK-MEL-2		Growth Inhibition Assay		IC50=809.44 nM	SANGER
SK-MEL-28	6.2 μM	Growth Inhibition Assay	72 h	GI50=1 μM	22435669
SK-MEL-28		Growth Inhibition Assay		IC50=10.0193 μM	SANGER
SK-MEL-3		Growth Inhibition Assay		IC50=3.82841 μM	SANGER
SK-MEL-30		Growth Inhibition Assay		IC50=11.4079 μM	SANGER
SK-MEL-5	6.2 μM	Growth Inhibition Assay	72 h	GI50=0.63 μM	22435669
SKMES1		Cytotoxic Assay	72 h	IC50=2.42 μM	19093884
SK-MES-1		Growth Inhibition Assay		IC50=7.05427 μM	SANGER
SK-N-AS		Growth Inhibition Assay		IC50=988.1 nM	SANGER
SK-N-DZ		Growth Inhibition Assay		IC50=900.43 nM	SANGER
SK-NEP-1		Growth Inhibition Assay		IC50=1.41693 μM	SANGER
SK-N-FI		Growth Inhibition Assay		IC50=4.94421 μM	SANGER
SKOV3		Cytotoxic Assay	72 h	Cytotoxicity against human SKOV3 cells overexpressing HER2 with IC50 of 2.2 μM	21080629
SKOV3	6.2 μM	Growth Inhibition Assay	72 h	GI50=1 μM	22435669
SK-OV-3		Cytotoxic Assay	72 h	IC50=2.2 μM	17691763
SK-PN-DW		Growth Inhibition Assay		IC50=17.4201 μM	SANGER
SK-UT-1		Growth Inhibition Assay		IC50=5.27751 μM	SANGER
SMMC7721		Growth Inhibition Assay	72 h	GI90=20 μM	23061376
SN12C	6.2 μM	Growth Inhibition Assay	72 h	GI50=2 μM	22435669
SN12C		Growth Inhibition Assay		IC50=2.43214 μM	SANGER
SNB19	6.2 μM	Growth Inhibition Assay	72 h	GI50=0.63 μM	22435669
SNB75	6.2 μM	Growth Inhibition Assay	72 h	GI50=0.79 μM	22435669
SNB75		Growth Inhibition Assay		IC50=15.0729 μM	SANGER
SNB78		Growth Inhibition Assay		EC50=16 μM	18247554
SNB78		Growth Inhibition Assay	48 h	GI50=16 μM	19419205
SNB-78		Growth Inhibition Assay	48 h	IC50=16 μM	15715470
SNU-387		Growth Inhibition Assay		IC50=7.85347 μM	SANGER
SNU-423		Growth Inhibition Assay		IC50=1.75827 μM	SANGER
SNU-449		Growth Inhibition Assay		IC50=2.89182 μM	SANGER
SNU-C2B		Growth Inhibition Assay		IC50=4.24769 μM	SANGER
SQ20B		Growth Inhibition Assay		IC50=3 μM	18247554
SR	6.2 μM	Growth Inhibition Assay	72 h	GI50=0.4 μM	22435669
ST14A	5 nM	Function Assay	72 h	Increase in REST/NRSF mRNA expression	17565993
ST14A	5 nM	Function Assay	72 h	Increase in E2F1 mRNA expression	17565993
St4		Growth Inhibition Assay		EC50=5.2 μM	18247554
St-4		Growth Inhibition Assay	48 h	IC50=5.2 μM	15715470
SU 86.86	50 μM	Cytotoxic Assay	72h	IC50=1.3 μM	18494463
SW1088		Growth Inhibition Assay		IC50=5.02944 μM	SANGER
SW1116		Growth Inhibition Assay		IC50=3.46269 μM	SANGER
SW13		Growth Inhibition Assay		IC50=3.07847 μM	SANGER
SW1417		Growth Inhibition Assay		IC50=25.2498 μM	SANGER
SW1573		Growth Inhibition Assay		IC50=2.96082 μM	SANGER
SW1710		Growth Inhibition Assay		IC50=5.41554 μM	SANGER
SW1783		Growth Inhibition Assay		IC50=14.2391 μM	SANGER
SW48		Growth Inhibition Assay		IC50=3.65657 μM	SANGER
SW620		Cytotoxic Assay	48 h	GI=0.54 μM	24015327
SW620		Growth Inhibition Assay		IC50=1.29018 μM	SANGER
SW626		Growth Inhibition Assay		IC50=1.94899 μM	SANGER
SW684		Growth Inhibition Assay		IC50=9.46116 μM	SANGER
SW756		Growth Inhibition Assay		IC50=3.29629 μM	SANGER
SW780		Growth Inhibition Assay		IC50=4.85766 μM	SANGER
SW837		Growth Inhibition Assay		IC50=5.37878 μM	SANGER
SW872		Growth Inhibition Assay		IC50=15.2218 μM	SANGER
SW900		Growth Inhibition Assay		IC50=6.76221 μM	SANGER
SW948		Growth Inhibition Assay		IC50=2.18456 μM	SANGER
SW954		Growth Inhibition Assay		IC50=863.16 nM	SANGER
SW962		Growth Inhibition Assay		IC50=4.78011 μM	SANGER
SW982		Growth Inhibition Assay		IC50=3.80551 μM	SANGER
T24		Kinase Assay	3 h	Induction of histone H3 acetylation with EC50 of 0.12 μM	19084395
T24		Kinase Assay	3 h	Induction of alpha tubulin acetylation with EC50 of 0.25 μM	19084395
T-24		Growth Inhibition Assay		IC50=3.1507 μM	SANGER
T47D	6.2 μM	Growth Inhibition Assay	72 h	GI50=0.5 μM	22435669
T47D		Growth Inhibition Assay		IC50=3.23627 μM	SANGER
T98G		Growth Inhibition Assay		IC50=4.22157 μM	SANGER
TCCSUP		Growth Inhibition Assay		IC50=1.72829 μM	SANGER
TE-1		Growth Inhibition Assay		IC50=791.1 nM	SANGER
TE-10		Growth Inhibition Assay		IC50=3.9201 μM	SANGER
TE-11		Growth Inhibition Assay		IC50=7.15184 μM	SANGER
TE-12		Growth Inhibition Assay		IC50=16.1873 μM	SANGER
TE-5		Growth Inhibition Assay		IC50=7.02881 μM	SANGER
TE-6		Growth Inhibition Assay		IC50=4.93977 μM	SANGER
TE-8		Growth Inhibition Assay		IC50=2.15765 μM	SANGER
TE-9		Growth Inhibition Assay		IC50=6.89847 μM	SANGER
TGBC11TKB		Growth Inhibition Assay		IC50=2.47177 μM	SANGER
TGBC1TKB		Growth Inhibition Assay		IC50=8.73535 μM	SANGER
TGBC24TKB		Growth Inhibition Assay		IC50=14.9539 μM	SANGER
TI-73		Growth Inhibition Assay		IC50=1.5906 μM	SANGER
TK10	6.2 μM	Growth Inhibition Assay	72 h	GI50=0.63 μM	22435669
TK10		Growth Inhibition Assay		IC50=3.13724 μM	SANGER
TSGH		Cytotoxic Assay	12 h	IC50=2.09 μM	24766560
TYK-nu		Growth Inhibition Assay		IC50=1.49851 μM	SANGER
U031		Growth Inhibition Assay		IC50=15.8028 μM	SANGER
U-118-MG		Growth Inhibition Assay		IC50=23.7217 μM	SANGER
U251		Cytotoxic Assay	48 h	GI=1.53 μM	24015327
U251		Growth Inhibition Assay		IC50=5.39096 μM	SANGER
U-266		Growth Inhibition Assay		IC50=2.77121 μM	SANGER
U-2-OS		Growth Inhibition Assay		IC50=1.07911 μM	SANGER
U87MG		Cytotoxic Assay	72 h	IC50=11 μM	17691763
U-87-MG		Growth Inhibition Assay		IC50=20.6413 μM	SANGER
U937	5 μM	Function Assay	24 h	Cell cycle arrest by accumulation at S/G2/M phase	17004718
U937	5 μM	Function Assay	24 h	Increase in histone H3 acetylation	17447750
U937	1 μM	Function Assay	24 h	Effect on alpha tubulin acetylation	17447750
U937	5 μM	Function Assay	24 h	Induction of histone H4 hyperacetylation	18381238
U937	5 μM	Function Assay	24 h	Induction of alpha tubulin hyperacetylation	18381238
U937	5 μM	Function Assay	24 h	Induction of p21 expression	18381238
U937	5 μM	Function Assay	24 h	Induction of apoptosis	18381238
U937	5 μM	Function Assay	24 h	Induction of granulocytic differentiation	18381238
U937	5 μM	Kinase Assay	24 h	Inhibition of human HDAC1	18381238
U937	5 μM	Kinase Assay	24 h	Inhibition of human HDAC4	18381238
U937		Growth Inhibition Assay	72 h	GI50=0.39 μM	20884208
U937	5 μM	Kinase Assay	24 h	Inhibition of histone acetyltransferase assessed as increase of acetylation of histone H3 at K9	21292492
U937	5 μM	Kinase Assay	24 h	Inhibition of histone acetyltransferase assessed as increase of acetylation of histone H3 at K18	21292492
U937	5 μM	Kinase Assay	24 h	Inhibition of histone acetyltransferase assessed as increase of pan-acetylated histone H4 level	21292492
U937	5 μM	Kinase Assay	15 min	Inhibition of histone acetyltransferase assessed as increase of histone H3 acetylation level	21292492
U937	5 μM	Kinase Assay	24 h	has no effect on alpha tubulin acetylation	17447750
U937	1 μM	Kinase Assay	24 h	has no effect on alpha tubulin acetylation	17447750
UACC257	6.2 μM	Growth Inhibition Assay	72 h	GI50=0.5 μM	22435669
UACC-257		Growth Inhibition Assay		IC50=5.02845 μM	SANGER
UACC62	6.2 μM	Growth Inhibition Assay	72 h	GI50=0.4 μM	22435669
UACC-62		Growth Inhibition Assay		IC50=42.5505 μM	SANGER
UACC-893		Growth Inhibition Assay		IC50=23.1038 μM	SANGER
UM-UC-3		Growth Inhibition Assay		IC50=5.62651 μM	SANGER
UO31	6.2 μM	Growth Inhibition Assay	72 h	GI50=0.5 μM	22435669
VA-ES-BJ		Growth Inhibition Assay		IC50=1.32477 μM	SANGER
Vero		Growth Inhibition Assay	72 h	IC50=0.9 μM	23786452
VM-CUB-1		Growth Inhibition Assay		IC50=1.19108 μM	SANGER
VMRC-RCZ		Growth Inhibition Assay		IC50=36.3022 μM	SANGER
WM-115		Growth Inhibition Assay		IC50=3.78195 μM	SANGER
YAPC		Growth Inhibition Assay		IC50=33.7648 μM	SANGER
YH-13		Growth Inhibition Assay		IC50=1.49894 μM	SANGER
YKG-1		Growth Inhibition Assay		IC50=2.45437 μM	SANGER
ZR-75-30		Growth Inhibition Assay		IC50=19.0968 μM	SANGER

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT00771472	Lymphoma	Phase 1	Completed	-	-
NCT00771472	-		Completed	-	-
NCT01064921	Stage III Squamous Cell Carcin... 展开 >>oma of the Oropharynx Stage IV Squamous Cell Carcinoma of the Oropharynx 收起 <<	Phase 1	Completed	-	United States, Ohio ... 展开 >> The Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43210 收起 <<
NCT00731731	Adult Giant Cell Glioblastoma ... 展开 >> Adult Glioblastoma Adult Gliosarcoma Cognitive Side Effects of Cancer Therapy 收起 <<	Phase 1 Phase 2	Active, not recruiting	-	-
NCT01567709	Adult B Acute Lymphoblastic Le... 展开 >>ukemia Adult T Acute Lymphoblastic Leukemia Anaplastic Large Cell Lymphoma Angioimmunoblastic T-Cell Lymphoma Chronic Lymphocytic Leukemia Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue Hepatosplenic T-Cell Lymphoma Intraocular Lymphoma Lymphomatous Involvement of Non-Cutaneous Extranodal Site Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma Nodal Marginal Zone Lymphoma Primary Cutaneous B-Cell Non-Hodgkin Lymphoma Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Adult Burkitt Lymphoma Recurrent Adult Grade III Lymphomatoid Granulomatosis Recurrent Adult Hodgkin Lymphoma Recurrent Adult Immunoblastic Lymphoma Recurrent Adult Lymphoblastic Lymphoma Recurrent Adult T-Cell Leukemia/Lymphoma Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Grade 3 Follicular Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Marginal Zone Lymphoma Recurrent Mycosis Fungoides and Sezary Syndrome Recurrent Non-Hodgkin Lymphoma Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma Recurrent Small Lymphocytic Lymphoma Refractory Chronic Lymphocytic Leukemia Refractory Hairy Cell Leukemia Small Intestinal Lymphoma Splenic Marginal Zone Lymphoma T-Cell Large Granular Lymphocyte Leukemia Testicular Lymphoma Waldenstrom Macroglobulinemia 收起 <<	Phase 1	Completed	-	United States, California ... 展开 >> City of Hope Comprehensive Cancer Center Duarte, California, United States, 91010 USC / Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 University of California Davis Comprehensive Cancer Center Sacramento, California, United States, 95817 United States, Pennsylvania Penn State Milton S Hershey Medical Center Hershey, Pennsylvania, United States, 17033-0850 University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States, 15232 收起 <<
NCT00479232	Leukemia, Myelocytic, Acute My... 展开 >>elodysplastic Syndromes Myelodysplastic Syndromes 收起 <<	Phase 1	Completed	-	-
NCT00731731	-		Active, not recruiting	-	-
NCT01267240	Paranasal Sinus Squamous Cell ... 展开 >>Carcinoma Recurrent Hypopharyngeal Squamous Cell Carcinoma Recurrent Laryngeal Squamous Cell Carcinoma Recurrent Oral Cavity Squamous Cell Carcinoma Recurrent Oropharyngeal Squamous Cell Carcinoma Stage IVA Hypopharyngeal Squamous Cell Carcinoma Stage IVA Laryngeal Squamous Cell Carcinoma Stage IVA Oral Cavity Squamous Cell Carcinoma Stage IVA Oropharyngeal Squamous Cell Carcinoma Stage IVB Hypopharyngeal Squamous Cell Carcinoma Stage IVB Laryngeal Squamous Cell Carcinoma Stage IVB Oral Cavity Squamous Cell Carcinoma Stage IVB Oropharyngeal Squamous Cell Carcinoma Stage IVC Hypopharyngeal Squamous Cell Carcinoma Stage IVC Laryngeal Squamous Cell Carcinoma Stage IVC Oral Cavity Squamous Cell Carcinoma Stage IVC Oropharyngeal Squamous Cell Carcinoma 收起 <<	Phase 2	Terminated(Study treatment did... 展开 >> not show clinical activity.) 收起 <<	-	United States, California ... 展开 >> Tower Cancer Research Foundation Beverly Hills, California, United States, 90211-1850 City of Hope Comprehensive Cancer Center Duarte, California, United States, 91010 USC / Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 Contra Costa Regional Medical Center Martinez, California, United States, 94553-3156 Veterans Administration Hospital - Martinez Martinez, California, United States, 94553 University of California Davis Comprehensive Cancer Center Sacramento, California, United States, 95817 City of Hope South Pasadena South Pasadena, California, United States, 91030 United States, Pennsylvania Penn State Milton S Hershey Medical Center Hershey, Pennsylvania, United States, 17033-0850 University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States, 15232 Canada, Alberta Tom Baker Cancer Centre Calgary, Alberta, Canada, T2N 4N2 Canada, British Columbia BCCA-Vancouver Cancer Centre Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Ontario Juravinski Cancer Centre at Hamilton Health Sciences Hamilton, Ontario, Canada, L8V 5C2 London Health Sciences Centre-Corporate London, Ontario, Canada, N6A 4L6 London Regional Cancer Program London, Ontario, Canada, N6A 4L6 收起 <<
NCT02538510	Head and Neck Squamous Cell Ca... 展开 >>rcinoma Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma Recurrent Nasopharynx Carcinoma Recurrent Salivary Gland Carcinoma Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary Stage III Major Salivary Gland Carcinoma Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma Stage III Nasopharyngeal Carcinoma Stage IV Nasopharyngeal Carcinoma Stage IVA Major Salivary Gland Carcinoma Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma Stage IVB Major Salivary Gland Carcinoma Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma Stage IVC Major Salivary Gland Carcinoma Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma 收起 <<	Phase 1 Phase 2	Active, not recruiting	June 30, 2019	United States, Washington ... 展开 >> Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States, 98109 收起 <<
NCT00128102	Mesothelioma ... 展开 >>Lung Cancer 收起 <<	Phase 3	Completed	-	-
NCT01281176	Adult Solid Neoplasm	Phase 1	Active, not recruiting	-	United States, Illinois ... 展开 >> University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States, 60637 收起 <<
NCT01208454	Localized Unresectable Neurobl... 展开 >>astoma Recurrent Neuroblastoma Regional Neuroblastoma Stage 4 Neuroblastoma Stage 4S Neuroblastoma 收起 <<	Phase 1	Completed	-	United States, California ... 展开 >> Children's Hospital Los Angeles Los Angeles, California, United States, 90027 Lucile Packard Children's Hospital Stanford University Palo Alto, California, United States, 94304 UCSF Medical Center-Parnassus San Francisco, California, United States, 94143 United States, Colorado Children's Hospital Colorado Aurora, Colorado, United States, 80045 United States, Georgia Children's Healthcare of Atlanta - Egleston Atlanta, Georgia, United States, 30322 United States, Illinois University of Chicago Comer Children's Hospital Chicago, Illinois, United States, 60637 United States, Massachusetts Boston Children's Hospital Boston, Massachusetts, United States, 02115 United States, Michigan C S Mott Children's Hospital Ann Arbor, Michigan, United States, 48109 United States, Ohio Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States, 45229 United States, Pennsylvania Children's Hospital of Philadelphia Philadelphia, Pennsylvania, United States, 19104 United States, Texas Cook Children's Medical Center Fort Worth, Texas, United States, 76104 United States, Washington Seattle Children's Hospital Seattle, Washington, United States, 98105 Canada, Ontario Hospital for Sick Children Toronto, Ontario, Canada, M5G 1X8 收起 <<
NCT01267240	-		Terminated(Study treatment did... 展开 >> not show clinical activity.) 收起 <<	-	-
NCT00268385	Adult Anaplastic Astrocytoma ... 展开 >> Adult Anaplastic Oligodendroglioma Adult Giant Cell Glioblastoma Adult Glioblastoma Adult Gliosarcoma Adult Mixed Glioma Recurrent Adult Brain Neoplasm 收起 <<	Phase 1	Active, not recruiting	-	United States, Alabama ... 展开 >> University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States, 35233 United States, California UCLA / Jonsson Comprehensive Cancer Center Los Angeles, California, United States, 90095 UCSF Medical Center-Mount Zion San Francisco, California, United States, 94115 United States, Florida Moffitt Cancer Center Tampa, Florida, United States, 33612 United States, Georgia Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States, 30322 United States, Maryland Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States, 21287 National Cancer Institute Neuro-Oncology Branch Bethesda, Maryland, United States, 20892 United States, Massachusetts Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, Michigan Henry Ford Hospital Detroit, Michigan, United States, 48202 United States, New York Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27710 Wake Forest University Health Sciences Winston-Salem, North Carolina, United States, 27157 United States, Ohio Cleveland Clinic Foundation Cleveland, Ohio, United States, 44195 United States, Pennsylvania University of Pennsylvania/Abramson Cancer Center Philadelphia, Pennsylvania, United States, 19104 University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States, 15232 United States, Texas M D Anderson Cancer Center Houston, Texas, United States, 77030 United States, Wisconsin University of Wisconsin Hospital and Clinics Madison, Wisconsin, United States, 53792 收起 <<
NCT00729118	Multiple Myeloma ... 展开 >> Plasma Cell Neoplasm 收起 <<	Phase 1	Active, not recruiting	December 31, 2018	United States, Ohio ... 展开 >> Ohio State University Columbus, Ohio, United States, 43210 收起 <<
NCT00132067	Primary Peritoneal Cavity Canc... 展开 >>er Recurrent Ovarian Epithelial Cancer 收起 <<	Phase 2	Completed	-	United States, Pennsylvania ... 展开 >> Gynecologic Oncology Group Philadelphia, Pennsylvania, United States, 19103 收起 <<
NCT01492881	Multiple Myeloma	Phase 2	Withdrawn(Doxil is currently u... 展开 >>navailable) 收起 <<	January 2017	United States, North Carolina ... 展开 >> Lineberger Comphrehensive Cancer Center at University of North Carolina at Chapel Hill Chapel Hill, North Carolina, United States, 27599 收起 <<
NCT01019850	Neuroblastoma	Phase 1	Completed	-	United States, California ... 展开 >> Children's Hospital Los Angeles Los Angeles, California, United States, 90027 Lucile Salter Packer Children's Hospital Palo Alto, California, United States, 94304 UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California, United States, 94143 United States, Georgia AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus Atlanta, Georgia, United States, 30322 United States, Illinois University of Chicago, Comer Children's Hospital Chicago, Illinois, United States, 60637 United States, Massachusetts Children's Hospital Boston Boston, Massachusetts, United States, 02115 United States, Michigan C.S Mott Children's Hospital Ann Arbor, Michigan, United States, 48109 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27710 United States, Ohio Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States, 45229-3039 United States, Pennsylvania Children's Hospital of Philadelphia Philadelphia, Pennsylvania, United States, 19104-4318 United States, Texas Cook Children's Medical Center - Fort Worth Fort Worth, Texas, United States, 76104 United States, Washington Children's Hospital and Regional Medical Center - Seattle Seattle, Washington, United States, 98105 收起 <<
NCT00731952	Non Small Cell Lung Cancer	Phase 1	Completed	-	United States, Virginia ... 展开 >> University of Virginia Charlottesville, Virginia, United States, 22908 收起 <<
NCT00798720	Carcinoma, Non Small Cell Lung	Phase 2	Completed	-	-
NCT00857324	Multiple Myeloma	Phase 1 Phase 2	Terminated(The Phase I of the ... 展开 >>study was completed, but Phase 2 has not been activated) 收起 <<	-	Italy ... 展开 >> Dipartimento Medicina Clinica e Sperimentale Padova, Italy, 35128 A.O.U. S. Giovanni Battista Torino, Italy, 10126 Policlinico Universitario di Udine Udine, Italy, 33100 Azienda Ospedaliera di Verona - Policlinico G.B. Rossi Verona, Italy, 37134 收起 <<
NCT00798720	-		Completed	-	-
NCT00907738	Advanced Cancer	Phase 2	Completed	-	-
NCT00907738	-		Completed	-	-
NCT00818649	-		Terminated(Met protocol stop r... 展开 >>ule [i.e., extreme toxicity]) 收起 <<	-	-
NCT00818649	Leukemia Myel... 展开 >>odysplastic Syndrome 收起 <<	Phase 2	Terminated(Met protocol stop r... 展开 >>ule [i.e., extreme toxicity]) 收起 <<	-	United States, Minnesota ... 展开 >> Masonic Cancer Center, University of Minnesota Minneapolis, Minnesota, United States, 55455 收起 <<
NCT00662311	-		Terminated	-	-
NCT00662311	Stage IIIA Non-small Cell Lung... 展开 >> Cancer Stage IIIB Non-small Cell Lung Cancer 收起 <<	Phase 1 Phase 2	Terminated	-	United States, Washington ... 展开 >> Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington, United States, 98109 收起 <<
NCT00810576	-		Terminated(Terminated due to s... 展开 >>low accrual.) 收起 <<	-	-
NCT03150329	Grade 3a Follicular Lymphoma ... 展开 >> Grade 3b Follicular Lymphoma Recurrent Classical Hodgkin Lymphoma Recurrent Diffuse Large B-Cell Lymphoma Recurrent Follicular Lymphoma Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma Refractory Classical Hodgkin Lymphoma Refractory Diffuse Large B-Cell Lymphoma Refractory Follicular Lymphoma Refractory Mediastinal (Thymic) Large B-Cell Cell Lymphoma 收起 <<	Phase 1	Recruiting	July 2019	United States, California ... 展开 >> City of Hope Medical Center Recruiting Duarte, California, United States, 91010 Contact: Alex F. Herrera, MD 626-256-4673 ext 62405 aherrera@coh.org Principal Investigator: Alex F. Herrera, MD United States, New Jersey Hackensack University Medical Center Recruiting Hackensack, New Jersey, United States, 07601 Contact: Tatyana Feldman, MD 551-996-4469 Tatyana.Feldman@hackensackmeridian.org Principal Investigator: Tatyana Feldman, MD 收起 <<
NCT00479232	-		Completed	-	-
NCT00810576	Lymphoma	Phase 2	Terminated(Terminated due to s... 展开 >>low accrual.) 收起 <<	-	United States, Texas ... 展开 >> UT MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT01600742	Brain Metastasis	Phase 2	Terminated(Sponsor stops to pr... 展开 >>ovide the study drug.) 收起 <<	-	Taiwan ... 展开 >> National Taiwan University Hospital Taipei, Taiwan, 100 收起 <<
NCT00918723	Chronic Lymphocytic Leukemia ... 展开 >> Stage I Chronic Lymphocytic Leukemia Stage I Small Lymphocytic Lymphoma Stage II Chronic Lymphocytic Leukemia Stage II Small Lymphocytic Lymphoma Stage III Chronic Lymphocytic Leukemia Stage III Small Lymphocytic Lymphoma Stage IV Chronic Lymphocytic Leukemia Stage IV Small Lymphocytic Lymphoma 收起 <<	Phase 1 Phase 2	Active, not recruiting	October 2019	United States, Washington ... 展开 >> Swedish Cancer Institute-Breast Center at First Hill Campus Seattle, Washington, United States, 98104 Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington, United States, 98109 收起 <<
NCT00918723	-		Active, not recruiting	-	-
NCT01039363	Acute Myeloid Leukemia	Phase 2	Unknown	-	Korea, Republic of ... 展开 >> Samsung Medical Center Not yet recruiting Seoul, Korea, Republic of, 135-710 Principal Investigator: Dong Hwan Won, M.D.,Ph.D. 收起 <<
NCT01118975	Breast Cancer ... 展开 >> Neoplasm Metastasis 收起 <<	Phase 1 Phase 2	Terminated(Lost sponsorship fo... 展开 >>r study drug) 收起 <<	-	United States, Maryland ... 展开 >> University of Maryland Greenebaum Cancer Center Baltimore, Maryland, United States, 21201 收起 <<
NCT01118975	-		Terminated(Lost sponsorship fo... 展开 >>r study drug) 收起 <<	-	-
NCT00565227	Non-Small-Cell Lung Carcinoma ... 展开 >> Prostate Cancer Bladder Cancer Urothelial Carcinoma 收起 <<	Phase 1	Terminated(closed due to toxic... 展开 >>ity) 收起 <<	-	United States, Michigan ... 展开 >> University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States, 48109 收起 <<
NCT00324740	-		Terminated	-	-
NCT01608139	Advanced Cancers	Phase 1	Withdrawn	-	-
NCT01421173	Lymphoma	Phase 1	Completed	-	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT00111813	Multiple Myeloma	Phase 1	Completed	-	-
NCT00785798	Relapsed Lymphomas ... 展开 >> Refractory Lymphomas 收起 <<	Phase 1 Phase 2	Terminated(sponsor requested)	-	United States, Connecticut ... 展开 >> Yale University School of Medicine New Haven, Connecticut, United States, 06520 收起 <<
NCT00111813	-		Completed	-	-
NCT01550224	-		Completed	-	-
NCT01550224	Acute Myeloid Leukemia With 11... 展开 >>q23-abnormality in Relapse 收起 <<	Phase 2	Completed	-	United States, California ... 展开 >> Stanford University Medical Center Stanford, California, United States, 94305 收起 <<
NCT01297764	Multiple Myeloma	Phase 1 Phase 2	Active, not recruiting	August 2019	United States, New Jersey ... 展开 >> Hackensack University Medical Center Hackensack, New Jersey, United States, 07601 收起 <<
NCT00324740	Recurrent Renal Cell Cancer ... 展开 >> Stage III Renal Cell Cancer Stage IV Renal Cell Cancer 收起 <<	Phase 1 Phase 2	Terminated	-	United States, New York ... 展开 >> Montefiore Medical Center - Moses Campus Bronx, New York, United States, 10467-2490 Weill Medical College of Cornell University New York, New York, United States, 10065 收起 <<
NCT00635791	Malignant Solid Tumour ... 展开 >> Renal Cell Carcinoma Non Small Cell Lung Carcinoma 收起 <<	Phase 1	Completed	-	United States, Colorado ... 展开 >> University of Colorado Cancer Center Aurora, Colorado, United States, 80045 收起 <<
NCT01728805	Cutaneous T-Cell Lymphoma	Phase 3	Active, not recruiting	December 2018	-
NCT00121225	Ciliary Body and Choroid Melan... 展开 >>oma, Medium/Large Size Extraocular Extension Melanoma Iris Melanoma Uveal Melanoma Recurrent Intraocular Melanoma Recurrent Melanoma Stage IV Melanoma 收起 <<	Phase 2	Completed	-	United States, Pennsylvania ... 展开 >> Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111-2497 Fox Chase Cancer Center Rockledge, Pennsylvania, United States, 19046 Canada, Ontario Juravinski Cancer Centre at Hamilton Health Sciences Hamilton, Ontario, Canada, L8V 5C2 Princess Margaret Hospital Phase 2 Consortium Toronto, Ontario, Canada, M5G 2M9 University Health Network-Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 收起 <<
NCT00785798	-		Terminated(sponsor requested)	-	-
NCT00486720	Myelodysplastic Syndromes ... 展开 >> Blood Disease Bone Marrow Disease 收起 <<	Phase 2	Terminated	-	-
NCT00910000	Ovarian Cancer ... 展开 >> Fallopian Tube Cancer Peritoneal Cancer 收起 <<	Phase 1 Phase 2	Terminated(Terminated due to u... 展开 >>nacceptable toxicity) 收起 <<	-	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 收起 <<
NCT00486720	-		Terminated	-	-
NCT00121225	-		Completed	-	-
NCT00910000	-		Terminated(Terminated due to u... 展开 >>nacceptable toxicity) 收起 <<	-	-
NCT01000155	Sickle Cell Disease ... 展开 >> Sickle Cell Anemia 收起 <<	Phase 2	Terminated(The study terminate... 展开 >>d early due to slow accrual.) 收起 <<	-	United States, Massachusetts ... 展开 >> Brigham and Women's Hospital Boston, Massachusetts, United States, 02115 Children's Hospital Boston Boston, Massachusetts, United States, 02115 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 收起 <<
NCT01000155	-		Terminated(The study terminate... 展开 >>d early due to slow accrual.) 收起 <<	-	-
NCT01587352	Ocular Melanoma With Extraocul... 展开 >>ar Extension Recurrent Uveal Melanoma Stage IV Uveal Melanoma AJCC v7 收起 <<	Phase 2	Terminated	-	United States, New York ... 展开 >> Columbia University/Herbert Irving Cancer Center New York, New York, United States, 10032 Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 United States, Tennessee Vanderbilt University/Ingram Cancer Center Nashville, Tennessee, United States, 37232 收起 <<
NCT00503971	Non-small Cell Lung Cancer	Phase 1 Phase 2	Terminated	-	Spain ... 展开 >> Hospital de la Santa Creu i Sant Pau Barcelona, Spain, 08025 Instituto Universitario Dexeus Barcelona, Spain, 08028 Hospital Clinic Barcelona, Spain, 08036 Institut Catalá d'Oncologia, Centre Sanitari i Universitari de Bellvitge (CSUB) Barcelona, Spain, 08907 Institut Catalá d'Oncología, Hospital Germans Trias i Pujol Barcelona, Spain, 08916 Hospital La Paz Madrid, Spain, 28046 Hospital Clínico Universitario de Valencia Valencia, Spain, 46010 Hospital Clínico Lozano Blesa Zaragoza, Spain, 50009 收起 <<
NCT00773838	Relapsed or Refractory Multipl... 展开 >>e Myeloma 收起 <<	Phase 2	Completed	-	-
NCT00776503	Myelodysplastic Syndromes	Phase 1 Phase 2	Completed	-	France ... 展开 >> Hôpital de la Durance Avignon, France, 84902 Hopital Avicenne Bobigny, France, 93009 CH René Dubos Cergy-pontoise, France, 95303 Hematology Dpt, Hôpital Sud Francilien Corbeil-essonnes, France, 91100 CHU Grenoble Grenoble, France, 38043 Hôpital Edouard Heriot, dpt Hématologie Clinique Lyon, France, 69437 Hematology Dpt, Institut Paoli Calmettes Marseille, France, 13009 Hematology Dpt, Hopital de l'Hotel Dieu Nantes, France, 44093 Hematology Dpt, Hopital Saint Louis Paris, France, 75475 Hematology Dpt, Hopital Cochin Paris, France, 75679 Centre Henri Bequerel Rouen, France, 76038 Centre René Huguenin Saint Cloud, France, 92210 Hematology Dpt, Hopital Haute Pierre Strasbourg, France, 67098 Hematology Dpt, Hopital Purpan Toulouse, France, 40031 收起 <<
NCT00773747	Multiple Myeloma	Phase 3	Completed	-	-
NCT00810602	-		Completed	-	-
NCT01110876	Brain Cancer ... 展开 >>Glioblastoma Multiforme 收起 <<	Phase 1 Phase 2	Terminated(Unanticipated Toxic... 展开 >>ities) 收起 <<	-	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT01790568	-		Completed	-	-
NCT00561418	Lymphoma Smal... 展开 >>l Intestine Cancer 收起 <<	Phase 1	Completed	-	United States, Ohio ... 展开 >> Ohio State University Medical Center Columbus, Ohio, United States, 43210 收起 <<
NCT00810602	Hematologic Malignancies ... 展开 >> Graft vs Host Disease 收起 <<	Phase 1 Phase 2	Completed	-	United States, Michigan ... 展开 >> University of Michigan Cancer Center Ann Arbor, Michigan, United States, 48109 United States, Missouri Washington University School of Medicine St. Louis, Missouri, United States, 63110 收起 <<
NCT00561418	-		Completed	-	-
NCT01319383	HIV-1 Infection	Phase 1 Phase 2	Completed	-	United States, North Carolina ... 展开 >> The University of North Carolina at Chapel Hill Chapel Hill, North Carolina, United States, 27514 收起 <<
NCT01790568	Graft vs Host Disease ... 展开 >> Hematologic Neoplasms Non-Neoplastic Hematologic and Lymphocytic Disorder 收起 <<	Phase 2	Completed	-	United States, Michigan ... 展开 >> University of Michigan Cancer Center Ann Arbor, Michigan, United States, 48109 收起 <<
NCT00667082	Non-Small Cell Lung Cancer ... 展开 >> Pancreatic Cancer Melanoma Lymphoma Multiple Myeloma 收起 <<	Phase 1	Completed	-	Australia, South Australia ... 展开 >> Royal Adelaide Hospital Adelaide, South Australia, Australia, 5000 The Queen Elizabeth Hospital Woodville South, South Australia, Australia, 5011 Australia, Western Australia Sir Charles Gairdner Hospital and University of Western Australia Nedlands, Western Australia, Australia, 6009 收起 <<
NCT01534260	-		Completed	-	-
NCT01266057	Advanced Cancers	Phase 1	Active, not recruiting	April 2019	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT01187446	-		Terminated(Business decision b... 展开 >>y funding source) 收起 <<	-	-
NCT01187446	Cutaneous Lymphoma ... 展开 >> Cutaneous T-cell Lymphoma 收起 <<	Phase 1 Phase 2	Terminated(Business decision b... 展开 >>y funding source) 收起 <<	-	United States, California ... 展开 >> Stanford University School of Medicine Stanford, California, United States, 94305 United States, Connecticut Yale University School of Medicine New Haven, Connecticut, United States, 06520 United States, Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT01422499	Children With Relapsed Solid T... 展开 >>umor, Lymphoma or Leukemia 收起 <<	Phase 1 Phase 2	Completed	-	Germany ... 展开 >> Clinic for Pediatric Oncology, Hematology, Immunology and Clinical Cooperation Unit Pediatric Oncology Heidelberg, BW, Germany, 69198 Childrens's Hospital, Pediatric Oncology and Hematology Augsburg, Germany, 86156 Prof. Hess Childrens's Hospital, Pediatric Oncology and Hematology Bremen, Germany, 28205 University Childrens's Hospital, Pediatric Oncology and Hematology Essen, Germany, 45122 University Children's Hospital, Clinic IV Freiburg, Germany, 79106 Department of Pediatric Oncology and Hematology University Hospital Eppendorf (UKE) Hamburg, Germany, 20246 University Children's Hospital, Pediatric Oncology and Hematology, MHH Hannover, Germany, 30625 University Childrens's Hospital, Pediatric Oncology and Hematology Jena, Germany, 07743 University Children's Hospital, Pediatric Oncology and Hematology Köln, Germany, 50937 Department of Pediatric Oncology and Hematology University Children's Hospital Münster, Germany, 48149 收起 <<
NCT01319383	-		Completed	-	-
NCT01534260	Acute Myeloid Leukemia	Phase 1 Phase 2	Completed	-	United States, Indiana ... 展开 >> Indiana University Melvin and Bren Simon Cancer Center Indianapolis, Indiana, United States, 46202 收起 <<
NCT00499811	Adult Grade III Lymphomatoid G... 展开 >>ranulomatosis Adult Nasal Type Extranodal NK/T-cell Lymphoma Anaplastic Large Cell Lymphoma Angioimmunoblastic T-cell Lymphoma Cutaneous B-cell Non-Hodgkin Lymphoma Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue Intraocular Lymphoma Nodal Marginal Zone B-cell Lymphoma Primary Central Nervous System Hodgkin Lymphoma Primary Central Nervous System Non-Hodgkin Lymphoma Recurrent Adult Burkitt Lymphoma Recurrent Adult Diffuse Large Cell Lymphoma Recurrent Adult Diffuse Mixed Cell Lymphoma Recurrent Adult Diffuse Small Cleaved Cell Lymphoma Recurrent Adult Grade III Lymphomatoid Granulomatosis Recurrent Adult Hodgkin Lymphoma Recurrent Adult Immunoblastic Large Cell Lymphoma Recurrent Adult Lymphoblastic Lymphoma Recurrent Adult T-cell Leukemia/Lymphoma Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Grade 3 Follicular Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Marginal Zone Lymphoma Recurrent Mycosis Fungoides/Sezary Syndrome Recurrent Small Lymphocytic Lymphoma Small Intestine Lymphoma Splenic Marginal Zone Lymphoma Stage III Adult Burkitt Lymphoma Stage III Adult Diffuse Large Cell Lymphoma Stage III Adult Diffuse Mixed Cell Lymphoma Stage III Adult Diffuse Small Cleaved Cell Lymphoma Stage III Adult Hodgkin Lymphoma Stage III Adult Immunoblastic Large Cell Lymphoma Stage III Adult Lymphoblastic Lymphoma Stage III Adult T-cell Leukemia/Lymphoma Stage III Cutaneous T-cell Non-Hodgkin Lymphoma Stage III Grade 1 Follicular Lymphoma Stage III Grade 2 Follicular Lymphoma Stage III Grade 3 Follicular Lymphoma Stage III Mantle Cell Lymphoma Stage III Marginal Zone Lymphoma Stage III Mycosis Fungoides/Sezary Syndrome Stage III Small Lymphocytic Lymphoma Stage IV Adult Burkitt Lymphoma Stage IV Adult Diffuse Large Cell Lymphoma Stage IV Adult Diffuse Mixed Cell Lymphoma Stage IV Adult Diffuse Small Cleaved Cell Lymphoma Stage IV Adult Hodgkin Lymphoma Stage IV Adult Immunoblastic Large Cell Lymphoma Stage IV Adult Lymphoblastic Lymphoma Stage IV Adult T-cell Leukemia/Lymphoma Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma Stage IV Grade 1 Follicular Lymphoma Stage IV Grade 2 Follicular Lymphoma Stage IV Grade 3 Follicular Lymphoma Stage IV Mantle Cell Lymphoma Stage IV Marginal Zone Lymphoma Stage IV Mycosis Fungoides/Sezary Syndrome Stage IV Small Lymphocytic Lymphoma Unspecified Adult Solid Tumor, Protocol Specific Waldenström Macroglobulinemia 收起 <<	Phase 1	Completed	-	United States, California ... 展开 >> City of Hope Medical Center Duarte, California, United States, 91010 University of Southern California Los Angeles, California, United States, 90033 United States, Georgia Emory University/Winship Cancer Institute Atlanta, Georgia, United States, 30322 United States, Maryland National Institutes of Health Bethesda, Maryland, United States, 20892 United States, Michigan Wayne State University-Karmanos Cancer Institute Detroit, Michigan, United States, 48201 United States, New York Montefiore Medical Center Bronx, New York, United States, 10467-2490 United States, Ohio Case Western Reserve University Cleveland, Ohio, United States, 44106 United States, Pennsylvania Penn State Milton S Hershey Medical Center Hershey, Pennsylvania, United States, 17033-0850 University of Pittsburgh Pittsburgh, Pennsylvania, United States, 15232 United States, West Virginia West Virginia University Healthcare Morgantown, West Virginia, United States, 26506 United States, Wisconsin University of Wisconsin Hospital and Clinics Madison, Wisconsin, United States, 53792 收起 <<
NCT00772798	Ovarian Cancer	Phase 2	Unknown	June 2009	Denmark ... 展开 >> Department of Oncology R Recruiting Odense, Denmark, DK-5000 C 收起 <<
NCT01059552	Locally Advanced Non-small Cel... 展开 >>l Lung Cancer 收起 <<	Phase 1	Active, not recruiting	December 1, 2018	United States, Florida ... 展开 >> Moffitt Cancer Center Tampa, Florida, United States, 33612 United States, Pennsylvania Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111 United States, South Carolina Medical University of South Carolina Charleston, South Carolina, United States, 29425 收起 <<
NCT00667615	-		Completed	-	-
NCT01502085	Multiple Myeloma	Phase 1 Phase 2	Unknown	May 2016	United States, New Jersey ... 展开 >> John Theurer Cancer Center at Hackensack University Medical Center Hackensack, New Jersey, United States, 07601 收起 <<
NCT00667615	Hodgkin's Disease ... 展开 >> Lymphoma 收起 <<	Phase 1 Phase 2	Completed	-	United States, New Jersey ... 展开 >> Memorial Sloan Kettering Cancer Center @ BaskingRidge Basking Ridge, New Jersey, United States, 07920 United States, New York Memorial Sloan Kettering Cancer Center @ Suffolk Commack, New York, United States, 11725 Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Weill Cornell Medical Center New York, New York, United States Memorial Sloan Kettering Cancer Center @ Phelps Sleepy Hollow, New York, United States, 10591 收起 <<
NCT02638090	Lung Cancer N... 展开 >>on-small Cell Lung Cancer 收起 <<	Phase 1 Phase 2	Recruiting	November 2020	United States, Florida ... 展开 >> H. Lee Moffitt Cancer Center and Research Institute Recruiting Tampa, Florida, United States, 33612 Contact: Germaine Gonzalez-Vazquez 813-745-6636 germaine.gonzalezvazquez@moffitt.org Contact: Jhanelle Gray, M.D. 813-745-7282 jhanelle.gray@moffitt.org Principal Investigator: Jhanelle Gray, M.D. Sub-Investigator: Scott Antonia, M.D., Ph.D. Sub-Investigator: Ben Creelan, M.D. Sub-Investigator: Eric Haura, M.D. Sub-Investigator: Tawee Tanvetyanon, M.D. Sub-Investigator: Charles Williams, Jr., M.D. 收起 <<
NCT00697476	Small Cell Lung Cancer	Phase 1 Phase 2	Terminated(insufficient enroll... 展开 >>ment) 收起 <<	-	Italy ... 展开 >> Istituto Clinico Humanitas Rozzano, Milan, Italy, 20089 收起 <<
NCT00831493	-		Terminated(Slow Accrual.)	-	-
NCT00972842	Peripheral T-Cell Non-Hodgkin'... 展开 >>s Lymphoma 收起 <<	Phase 1 Phase 2	Terminated(slow recruitment)	-	Austria ... 展开 >> Medizinische Universitaet Innsbruck, Abtlg. f. Haematologie und Onkologie Innsbruck, Tirol, Austria, A-6020 Krankenhaus der Elisabethinen Linz Linz, Austria, A-4010 Krankenhaus der Stadt Linz Linz, Austria, A-4020 Universitaetsklinik f. Innere Medizin III Salzburg, Austria, A-5020 Hanusch Krankenhaus Vienna, Austria, A-1140 收起 <<
NCT02420613	Diffuse Intrinsic Pontine Glio... 展开 >>ma 收起 <<	Phase 1	Recruiting	October 2020	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 收起 <<
NCT00831493	Pancreatic Cancer	Phase 1 Phase 2	Terminated(Slow Accrual.)	-	United States, Texas ... 展开 >> UT MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT00948688	-		Terminated(Funding was withdra... 展开 >>wn after only 10 participants were enrolled) 收起 <<	-	-
NCT01075113	Liver Cancer	Phase 1	Active, not recruiting	January 31, 2023	United States, Virginia ... 展开 >> Hunter Holmes McGuire VA Medical Center Richmond, Virginia, United States, 23249 Virginia Commonwealth University/Massey Cancer Center Richmond, Virginia, United States, 23298 收起 <<
NCT01276717	Lymphoma	Phase 1	Completed	-	United States, New York ... 展开 >> University of Rochester Rochester, New York, United States, 14642 United States, Virginia Virginia Commonwealth University Massey Cancer Center Richmond, Virginia, United States, 23298 收起 <<
NCT00948688	Pancreatic Cancer ... 展开 >> Adenocarcinoma of the Pancreas 收起 <<	Phase 1 Phase 2	Terminated(Funding was withdra... 展开 >>wn after only 10 participants were enrolled) 收起 <<	-	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 收起 <<
NCT00976183	-		Terminated(toxicities)	-	-
NCT00821951	-		Completed	-	-
NCT01266031	-		Completed	-	-
NCT01266031	Malignant Glioma ... 展开 >> Recurrent Glioblastoma 收起 <<	Phase 1 Phase 2	Completed	-	United States, Texas ... 展开 >> Baylor University Medical Center Dallas, Texas, United States, 75246 收起 <<
NCT01748240	Myelodysplastic Syndrome	Phase 2	Terminated(inefficiency)	-	France ... 展开 >> CHU d'Angers Angers, France, 49033 CH Annecy Annecy, France, 74374 Hôpital Avignon Avignon, France, 84000 Centre hospitalier de la côte Basque Bayonne, France, 64100 Hôpital Avicenne Bobigny, France, 93009 CHU de Haut-Lévèque Bordeaux Pessac, France, 33604 CHU de Grenoble Grenoble, France, 38043 CH Le mans Le mans, France, 72037 CH Lyon Sud Lyon, France, 69495 IPC-Unité d'Hématologie 3 Marseille, France, 13273 CHU Nantes Nantes, France, 44093 Hôpital Archet1 Nice, France, 06202 GHU Caremeau Nimes, France, 30029 Hôpital Saint Louis Paris, France, 75010 Hopital Saint Louis - AP-HP, Hematology Dpt Paris, France, 75475 Hôpital Saint-Louis Paris, France, 75475 Hopital Cochin-Hematology Paris, France, 75679 Centre Hospitalier Joffre Perpignan, France, 66046 Centre Henri Becquerel Rouen, France, 76038 Hopital Purpan-Medecine interne Toulouse, France, 31059 Hôpital PURPAN, Service d'Hématologie Clinique Toulouse, France, 31059 CHU Bretonneau Tours, France, 37044 CH de Valence Valence, France, 26953 CHU Brabois Vandoeuvre, France, 54511 收起 <<
NCT00976183	Ovarian Neoplasms	Phase 1 Phase 2	Terminated(toxicities)	-	United States, California ... 展开 >> Gynecologic Oncology Associates Newport Beach, California, United States, 92663 收起 <<
NCT01748240	-		Terminated(inefficiency)	-	-
NCT01339871	Advanced Cancer	Phase 1	Completed	-	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT02589145	Lymphoma	Phase 1 Phase 2	Active, not recruiting	June 2021	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT00821951	Non-Small Cell Lung Cancer (NS... 展开 >>CLC) 收起 <<	Phase 1	Completed	-	United States, Connecticut ... 展开 >> Yale University School of Medicine New Haven, Connecticut, United States, 06520 收起 <<
NCT03198559	HIV Infections	Phase 1 Phase 2	Suspended(Review of current ad... 展开 >>verse events reported by study participants) 收起 <<	July 2027	Australia, Victoria ... 展开 >> Department of Infectious Diseases, Alfred Hospital Melbourne, Victoria, Australia, 3004 收起 <<
NCT00838929	Brain Metastases	Phase 1	Completed	-	United States, Pennsylvania ... 展开 >> Thomas Jefferson University Philadelphia, Pennsylvania, United States, 19107 United States, Texas The University of Texas Southwestern Medical Center Dallas, Texas, United States, 75390 收起 <<
NCT00875745	Leukemia, Myeloid, Acute ... 展开 >> Leukemia, Promyelocytic, Acute Myelodysplastic Syndromes 收起 <<	Phase 1	Completed	-	United States, Indiana ... 展开 >> Indiana University Melvin and Bren Simon Cancer Center Indianapolis, Indiana, United States, 46202 收起 <<
NCT00801151	Malignant Solid Tumour	Phase 1	Terminated	-	France ... 展开 >> Centre René GAUDUCHEAU Nantes Saint Herblain, France, 44805 Institut Curie Paris, France, 75005 Institut Claudius REGAUD Toulouse, France, 31052 收起 <<
NCT00838929	-		Completed	-	-
NCT01194427	Stage I Breast Cancer ... 展开 >> Stage II Breast Cancer Stage III Breast Cancer Invasive Breast Cancer 收起 <<	Phase 2	Terminated(Difficulty meeting ... 展开 >>patient accrual goals) 收起 <<	-	United States, Maryland ... 展开 >> Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland, United States, 21287 收起 <<
NCT01194427	-		Terminated(Difficulty meeting ... 展开 >>patient accrual goals) 收起 <<	-	-
NCT01720875	Multiple Myeloma	Phase 2	Unknown	August 2017	United Kingdom ... 展开 >> Nottingham University Hospital Nottingham, Nottinghamshire, United Kingdom, NG5 1PB University Hospital Southampton Southampton, United Kingdom, SO16 6YD 收起 <<
NCT00735826	Aerodigestive Tract Cancer ... 展开 >> Lung Cancer Esophageal Cancer Head and Neck Cancer 收起 <<	Not Applicable	Completed	-	United States, New Hampshire ... 展开 >> Dartmouth-Hitchcock Medical Center Lebanon, New Hampshire, United States, 03756 收起 <<
NCT00735826	-		Completed	-	-
NCT01023737	Malignant Solid Tumour	Phase 1	Active, not recruiting	September 2020	United States, Texas ... 展开 >> Cancer Therapy & Research Center University of Texas Health Science Center San Antonio San Antonio, Texas, United States, 78229 收起 <<
NCT00918489	Soft Tissue Sarcoma	Phase 2	Completed	-	Germany ... 展开 >> Department of Hematology, Oncology, Rheumatology and Immunology, University Hospital Tübingen Tübingen, Baden-Württemberg, Germany, D-72076 Department of Hematology, Hemostaseology, Oncology and Stemm Cell Transplantation, Medical School Hannover Hannover, Niedersachen, Germany, D-30625 Department of Oncology, Hematology and Palliative Medicine, Marien Hospital Düsseldorf Düsseldorf, Nordrhein-Westfalen, Germany, D-40479 Comprehensive Cancer Center North, University Hospital Kiel Kiel, Germany, 24105 Sarcoma Center Mannheim, University Hospital Mannheim Mannheim, Germany, 68167 Center for Soft Tissue Sarcoma, University Hospital Tübingen Tübingen, Germany, 72074 Comprehensive Cancer Center Ulm (CCCU) Ulm, Germany, 89081 收起 <<
NCT00702962	-		Terminated(Poor accrual)	-	-
NCT02042989	Advanced Cancers	Phase 1	Active, not recruiting	June 2022	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT02124083	Neimann-Pick Disease	Phase 1 Phase 2	Completed	-	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT00702962	Small Cell Lung Cancer	Phase 1 Phase 2	Terminated(Poor accrual)	-	United States, Pennsylvania ... 展开 >> Penn State College of Medicine, Penn State Milton S. Hershey Medical Center Hershey, Pennsylvania, United States, 17033 收起 <<
NCT02151721	Non-Small-Cell Lung Carcinoma	Phase 1	Active, not recruiting	February 20, 2018	Japan ... 展开 >> Nagoya University Graduate School of Medicine Nagoya, Aichi, Japan, 466-8560 Institute of Biomedical Research and Innovation Hospital Kobe, Hyogo-ken, Japan, 650-0047 Kanazawa University Hospital Kanazawa, Ishikawa, Japan, 920-0934 Tohoku University Hospital Sendai, Miyagi, Japan, 980-8574 Shizuoka Cancer Center Sunto-gun, Shizuoka, Japan, 411-8777 收起 <<
NCT02619253	Renal Cell Carcinoma ... 展开 >> Urinary Bladder Neoplasms 收起 <<	Phase 1	Recruiting	May 31, 2020	United States, California ... 展开 >> USC/Norris Comprehensive Cancer Center Recruiting Los Angeles, California, United States, 90033 Contact: Charis Barg, RN 323-865-0845 charis.barg@med.usc.edu Principal Investigator: David Quinn, MD United States, Indiana Indiana University Hospital Recruiting Indianapolis, Indiana, United States, 46202 Contact: Marietta Moore, RN 317-274-7477 marlmoor@iu.edu Principal Investigator: Roberto Pili, MD Indiana University Melvin and Bren Simon Cancer Center Recruiting Indianapolis, Indiana, United States, 46202 Contact: Marietta Moore, RN 317-274-7477 marlmoor@iu.edu Principal Investigator: Roberto Pili, MD IU Health Central Indiana Cancer Centers (CICC) Recruiting Indianapolis, Indiana, United States, 46219 Contact: Deb Racster, RN 317-727-6549 dracster@iuhealth.org Principal Investigator: Andrew Greenspan, MD United States, Maryland Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Recruiting Baltimore, Maryland, United States, 21205 Contact: Connie Collins 410-955-1017 ccolli23@jhmi.edu Principal Investigator: Noah Hahn, MD 收起 <<
NCT02124083	-		Completed	-	-
NCT01365065	HIV Positive	Phase 2	Active, not recruiting	January 2018	Australia, Victoria ... 展开 >> The Alfred Hospital - Infectious Diseases Unit Melbourne, Victoria, Australia, 3004 收起 <<
NCT02836548	Melanoma Skin... 展开 >> Neoplasms 收起 <<	Phase 1 Phase 2	Recruiting	October 2019	Netherlands ... 展开 >> Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital Recruiting Amsterdam, Netherlands, 1066 CX Contact: N Steeghs, MD, PhD 收起 <<
NCT01294670	Solid Tumors ... 展开 >>Relapsed/Refractory Sarcomas 收起 <<	Phase 1 Phase 2	Active, not recruiting	February 2019	United States, Arizona ... 展开 >> Phoenix Children'S Hospital Phoenix, Arizona, United States, 85016 United States, Colorado Children's Hospital Colorado Aurora, Colorado, United States, 80045 United States, Florida Arnold Palmer Hospital for Children/MD Anderson Cancer Center Orlando Orlando, Florida, United States, 32806 All Children's Hospital Saint Petersburg, Florida, United States, 33701 United States, Maryland John Hopkins Medical Center Baltimore, Maryland, United States, 21287 United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, Missouri Children's Mercy Hospital & Clinics Kansas City, Missouri, United States, 64108 United States, New York Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 United States, Pennsylvania Pennsylvania State University College of Medicine Hershey, Pennsylvania, United States, 17110 United States, Texas Md Anderson Cancer Center Houston, Texas, United States, 77030 Canada, Alberta Alberta Children'S Hospital Calgary, Alberta, Canada, T2N 1N4 收起 <<
NCT02707900	HIV-1 Infection	Phase 1	Terminated(Manufacturing of th... 展开 >>e AGS-004 HIV vaccine by Argos could no longer be provided.) 收起 <<	-	United States, North Carolina ... 展开 >> University of North Carolina Hospitals Chapel Hill, North Carolina, United States, 27599-7030 收起 <<
NCT03742245	Breast Cancer Metastatic ... 展开 >> Breast Cancer 收起 <<	Phase 1	Not yet recruiting	September 1, 2022	United States, Texas ... 展开 >> Houston Methodist Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT01500538	Follicular Lymphoma ... 展开 >> Marginal Zone Lymphoma Mantle Cell Lymphoma 收起 <<	Phase 2	Terminated(Poor recruitment ra... 展开 >>te) 收起 <<	-	Australia, Victoria ... 展开 >> Peter MacCallum Cancer Centre Melbourne, Victoria, Australia, 3002 收起 <<
NCT03056495	Alzheimer Disease	Phase 1	Recruiting	October 2019	Germany ... 展开 >> German Center for Neurodegenerative Diseases Recruiting Bonn, Germany, 53127 Contact: Anja Schneider, Prof. Dr. med. 0049-228-287-1137 anja.schneider@dzne.de University Medical Center Göttingen, Department of Psychiatry and Psychotherapy Recruiting Göttingen, Germany, 37075 Contact: Jens Wiltfang, Prof. Dr. med. 0049-551-3966601 jens.wiltfang@med.uni-goettingen.de 收起 <<
NCT03509207	Leiomyosarcoma ... 展开 >> Endometrial Stromal Tumors Carcinosarcomas Uterine 收起 <<	Phase 2	Recruiting	December 31, 2019	Austria ... 展开 >> Medical University of Graz, Clinic of Obstetrics and Gynecology Recruiting Graz, Austria, 8036 Contact: Edgar Petru, Prof. MD +43 316 385 ext 13810 edgar.petru@medunigraz.at Principal Investigator: Edgar Petru, MD 收起 <<
NCT03022565	Uveal Melanoma	Early Phase 1	Recruiting	December 2025	United States, Florida ... 展开 >> University of Miami Recruiting Miami, Florida, United States, 33136 Contact: Andrea Pena 305-243-7592 a.palomino@med.miami.edu Contact: Lynn Feun, MD 305-243-6606 lfeun@med.miami.edu Principal Investigator: Lynn Feun, MD 收起 <<
NCT01578343	Mantle Cell Lymphoma	Phase 2	Terminated(we collected data o... 展开 >>f a total of 19 patients for an interim analysis. but there are less than 7 responses out of the initial 19 patients.) 收起 <<	-	Korea, Republic of ... 展开 >> Samsung Medical Center Seoul, Korea, Republic of, 135-710 收起 <<
NCT01045538	Gastric Cancer ... 展开 >> Histone Deacetylase Inhibitor 收起 <<	Phase 1 Phase 2	Completed	-	Korea, Republic of ... 展开 >> Asan Medical Center Seoul, Korea, Republic of, 138-736 收起 <<
NCT02645149	Melanoma	Phase 4	Not yet recruiting	August 2021	Australia, New South Wales ... 展开 >> Royal Prince Alfred Hospital Not yet recruiting Camperdown, New South Wales, Australia, 2050 Contact: Maria Gonzalez 612 9911 7200 maria.gonzalez@melanoma.org.au Principal Investigator: John Thompson Westmead Hospital Westmead, New South Wales, Australia, 2145 Melanoma Institute Australia Not yet recruiting Wollstonecraft, New South Wales, Australia, 2065 Contact: Maria Gonzalez +612 9911 7200 maria.gonzalez@melanoma.org.au Contact: Alex Menzies +612 9911 7200 info@melanoma.org.au Sub-Investigator: Georgina Long Principal Investigator: Alex Menzies 收起 <<
NCT01142375	-		Unknown	-	-
NCT00007345	Cutaneous T Cell Lymphoma ... 展开 >> Peripheral T Cell Lymphoma 收起 <<	Phase 2	Completed	-	United States, Arizona ... 展开 >> Mayo Clinic Scottsdale Scottsdale, Arizona, United States, 85259 United States, Arkansas University of Arkansas Little Rock, Arkansas, United States, 72205 United States, California City of Hope National Cancer Center Duarte, California, United States, 91010 Mercy General Hospital Sacramento, California, United States, 95819 United States, District of Columbia Georgetown University Washington, District of Columbia, United States, 20007-2197 United States, Illinois Northwestern University Chicago, Illinois, United States, 60611 United States, Maryland National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 United States, New York North Shore University Hospital Manhasset, New York, United States, 11030 United States, Pennsylvania University of Pittsburgh Pittsburgh, Pennsylvania, United States, 15261 United States, West Virginia West Virginia University Morgantown, West Virginia, United States, 26506 Australia Royal Adelaide Hospital Adelaide, Australia Peter MacCallum Cancer Centre Melbourne, Australia Sir Charles Gairdner Hospital Perth, Australia 收起 <<
NCT02788201	Urothelial Carcinoma ... 展开 >> Bladder Cancer Urinary Bladder Neoplasms 收起 <<	Phase 2	Recruiting	July 1, 2020	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office 888-624-1937 收起 <<
NCT00007345	-		Completed	-	-
NCT01655004	Breast Carcinoma	Not Applicable	Unknown	August 2018	Singapore ... 展开 >> National University Hospital Recruiting Singapore, Singapore, 119074 Contact: Andrea LA Wong, MBBS (65) 6772 5934 andrea_la_wong@nuhs.edu.sg Sub-Investigator: Soo Chin Lee, MBBS Sub-Investigator: Siew Eng Lim, MBBS Sub-Investigator: Sing Huang Tan, MBBS 收起 <<
NCT03117751	Acute Lymphoblastic Leukemia ... 展开 >> Acute Lymphoblastic Lymphoma 收起 <<	Phase 2 Phase 3	Recruiting	March 31, 2028	United States, Tennessee ... 展开 >> St. Jude Children's Research Hospital Recruiting Memphis, Tennessee, United States, 38105 Contact: Hiroto Inaba, MD, PhD 866-278-5833 referralinfo@stjude.org Principal Investigator: Hiroto Inaba, MD, PhD 收起 <<
NCT01663571	-		Terminated(Study is permanentl... 展开 >>y closed to enrollment .Collection of private identifiable information is complete Analysis of private identifiable information is complete) 收起 <<	-	United States, New York ... 展开 >> NYU Langone Medical Center New York, New York, United States, 10016 收起 <<
NCT02559778	Neuroblastoma	Phase 2	Recruiting	September 2026	-
NCT00858234	Multiple Myeloma	Phase 1	Completed	-	-
NCT02553460	Acute Lymphoblastic Leukemia	Phase 1 Phase 2	Recruiting	October 2031	United States, California ... 展开 >> Children's Hospital Los Angeles Recruiting Los Angeles, California, United States, 90027 Contact: Paul Gaynon, MD 323-361-4110 pgaynon@chla.usc.edu Principal Investigator: Paul Gaynon, MD Children's Hospital of Orange County Recruiting Orange, California, United States, 92868 Contact: Ivan Kirov, MD 714-997-3000 ikirov@choc.org Principal Investigator: Ivan Kirov, MD Lucile Packard Children's Hospital Stanford University Recruiting Palo Alto, California, United States, 94304 Contact: Norman J. Lacayo, MD 650-497-8953 lacayon@stanford.edu Principal Investigator: Norman J. Lacayo, MD Rady Children's Hospital and Health Center Recruiting San Diego, California, United States, 92123 Contact: Deborah Schiff, MD 858-966-5983 dschiff@chsd.org Principal Investigator: Deborah Schiff, MD United States, Minnesota Children's Hospital and Clinics of Minnesota Recruiting Minneapolis, Minnesota, United States, 55102 Contact: Michael Richards, MD 612-813-5193 Michael.richards@childrensmn.org Principal Investigator: Michael Richards, MD United States, North Carolina St. Jude Affiliate-Charlotte Recruiting Charlotte, North Carolina, United States, 28204 Contact: Christine Bolen, MD 704-384-1900 cybolen@novanthealth.org Principal Investigator: Christine Bolen, MD United States, Ohio Cincinnati Children's Hospital Recruiting Cincinnati, Ohio, United States, 45229 Contact: Erin Breese, MD, PhD 513-636-2799 erin.breese@cchmc.org Principal Investigator: Erin Breese, MD, PhD Rainbow Babies & Children's Hospital Recruiting Cleveland, Ohio, United States, 44106 Contact: Yousif Matloub, MD 216-844-5437 yousif.matloub@uhhospitals.org Principal Investigator: Yousif Matloub, MD United States, Oregon Oregon Health and Science University Recruiting Portland, Oregon, United States, 97239 Contact: Bill Chang, MD 503-494-1080 changb@ohsu.edu Principal Investigator: Bill Chang, MD United States, Tennessee St. Jude Children's Research Hospital Recruiting Memphis, Tennessee, United States, 38105 Contact: Tanja A. Gruber, MD, PhD 866-278-5833 tanja.gruber@stjude.org Contact: Referral Office 866-278-5833 referralinfo@stjude.org Principal Investigator: Tanja A. Gruber, MD, PhD United States, Virginia Children's Hospital of the King's Daughters (CHKD) Recruiting Norfolk, Virginia, United States, 23507 Contact: Eric Lowe, MD 757-668-7243 eric.lowe@chkd.org Principal Investigator: Eric Lowe, MD Canada, Alberta Alberta Children's Hospital Recruiting Calgary, Alberta, Canada, T3A 6A8 Contact: Victor A. Lewis, MD 403-220-6898 victor.lewis@ahs.ca Principal Investigator: Victor A. Lewis, MD Stollery Children's Hospital Recruiting Edmonton, Alberta, Canada, T6G 2B7 Contact: Sunil Desai, M.B.Ch.B., FRCP(c) 780-248-5415 sunil.desai@ahs.ca Principal Investigator: Sunil Desai, M.B.Ch.B., FRCP(c) Canada, British Columbia Children's & Women's Health Centre of British Columbia Recruiting Vancouver, British Columbia, Canada, V6H 3V4 Contact: Kirk R. Schultz, MD 604-875-2345 ext 6477 kschultz@mail.ubc.ca Principal Investigator: Kirk R. Schultz, MD Canada, Ontario McMaster Children's Hospital at Hamilton Health Sciences Recruiting Hamilton, Ontario, Canada, L85 4J9 Contact: Uma Athale, MD 905-521-2100 ext 73376 athaleu@mcmaster.ca Principal Investigator: Uma Athale, MD Canada, Quebec The Montreal Children's Hospital (MUHC-McGill) Recruiting Montreal, Quebec, Canada, H4A 3J1 Contact: Catherine Vezina, MD 514-412-4445 catherine.vezina@muhc.mcgill.ca Principal Investigator: Catherine Vezina, MD Centre Hospitalier Universitaire Sainte-Justine Recruiting Montreal, Quebec, Canada, HcT 1C5 Contact: Henrique Bittencourt, MD 514-345-4931 henrique.bittencourt.hsj@ssss.gouv.qc.ca Contact: Yvan Samson yvan.samson@umontreal.ca Principal Investigator: Henrique Bittencourt, MD Centre Hospitalier Universitaire de Quebec Recruiting Québec, Quebec, Canada, G1V 4G2 Contact: Bruno Michon, MD 418-525-4444 bruno.michon@mail.chuq.qc.ca Principal Investigator: Bruno Michon, MD 收起 <<
NCT03259503	Malignant Neoplasms Stated as ... 展开 >>Primary Lymphoid Haematopoietic Lymphoma 收起 <<	Phase 1 Phase 2	Not yet recruiting	May 2019	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Not yet recruiting Houston, Texas, United States, 77030 Contact ynieto@mdanderson.org 收起 <<
NCT01249443	HIV Infection ... 展开 >> Recurrent Anal Cancer Recurrent Breast Cancer Recurrent Esophageal Cancer Recurrent Gastric Cancer Recurrent Metastatic Squamous Neck Cancer With Occult Primary Recurrent Non-small Cell Lung Cancer Recurrent Ovarian Epithelial Cancer Recurrent Salivary Gland Cancer Recurrent Squamous Cell Carcinoma of the Hypopharynx Recurrent Squamous Cell Carcinoma of the Larynx Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity Recurrent Squamous Cell Carcinoma of the Nasopharynx Recurrent Squamous Cell Carcinoma of the Oropharynx Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Recurrent Verrucous Carcinoma of the Larynx Recurrent Verrucous Carcinoma of the Oral Cavity Salivary Gland Squamous Cell Carcinoma Stage IV Anal Cancer Stage IV Breast Cancer Stage IV Esophageal Cancer Stage IV Gastric Cancer Stage IV Non-small Cell Lung Cancer Stage IV Ovarian Epithelial Cancer Stage IV Salivary Gland Cancer Stage IV Squamous Cell Carcinoma of the Hypopharynx Stage IV Squamous Cell Carcinoma of the Larynx Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity Stage IV Squamous Cell Carcinoma of the Nasopharynx Stage IV Squamous Cell Carcinoma of the Oropharynx Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity Stage IV Verrucous Carcinoma of the Larynx Stage IV Verrucous Carcinoma of the Oral Cavity Unspecified Adult Solid Tumor, Protocol Specific 收起 <<	Phase 1	Terminated(Inadequate accrual ... 展开 >>rate) 收起 <<	-	United States, California ... 展开 >> UC San Diego Moores Cancer Center La Jolla, California, United States, 92093 UCLA Center for Clinical AIDS Research and Education Los Angeles, California, United States, 90035 United States, District of Columbia Lombardi Comprehensive Cancer Center at Georgetown University Washington, District of Columbia, United States, 20057 United States, Florida University of Miami Miller School of Medicine-Sylvester Cancer Center Miami, Florida, United States, 33136 United States, Illinois John H. Stroger Jr. Hospital of Cook County Chicago, Illinois, United States, 60612 United States, Massachusetts Boston Medical Center Boston, Massachusetts, United States, 02118 United States, Missouri Siteman Cancer Center at Washington University Saint Louis, Missouri, United States, 63110 United States, New York Montefiore Medical Center Bronx, New York, United States, 10467-2490 United States, Pennsylvania Pennsylvania Oncology Hematology Associates Philadelphia, Pennsylvania, United States, 19106 United States, Washington Benaroya Research Institute at Virginia Mason Seattle, Washington, United States, 98101-2795 收起 <<
NCT02114502	Myeloma	Phase 2	Withdrawn	-	-
NCT00424775	-		Terminated	-	-
NCT02336074	HIV	Phase 2	Active, not recruiting	November 2022	United Kingdom ... 展开 >> Brighton and Sussex University Hospitals NHS Trust Brighton, United Kingdom Central and North West London NHS Foundation Trust London, United Kingdom Chelsea and Westminster NHS Foundation Trust London, United Kingdom Guy's and St Thomas' NHS Foundation Trust London, United Kingdom Imperial College Healthcare NHS Trust London, United Kingdom Royal Free Hospital NHS Foundation Trust London, United Kingdom 收起 <<
NCT03382834	HIV Infections	Early Phase 1	Active, not recruiting	June 30, 2023	United States, Alabama ... 展开 >> Alabama CRS Birmingham, Alabama, United States, 35294 United States, California UCLA CARE Center CRS Los Angeles, California, United States, 90035 Ucsf Hiv/Aids Crs San Francisco, California, United States, 94110 Harbor-UCLA CRS Torrance, California, United States, 90502 United States, Colorado University of Colorado Hospital CRS Aurora, Colorado, United States, 80045 United States, District of Columbia Whitman-Walker Health CRS Washington, District of Columbia, United States, 20005 United States, Georgia The Ponce de Leon Center CRS Atlanta, Georgia, United States, 30308-2012 United States, Illinois Northwestern University CRS Chicago, Illinois, United States, 60611 United States, Massachusetts Massachusetts General Hospital CRS (MGH CRS) Boston, Massachusetts, United States, 02114 United States, New Jersey New Jersey Medical School Clinical Research Center CRS Newark, New Jersey, United States, 07103 United States, North Carolina Chapel Hill CRS Chapel Hill, North Carolina, United States, 27599 Greensboro CRS Greensboro, North Carolina, United States, 27401 United States, Ohio Cincinnati Clinical Research Site Cincinnati, Ohio, United States, 45219 United States, Pennsylvania Penn Therapeutics, CRS Philadelphia, Pennsylvania, United States, 19104 Puerto Rico Puerto Rico AIDS Clinical Trials Unit CRS San Juan, Puerto Rico, 00935 收起 <<
NCT02412475	Leukemia, Acute Myeloid	Phase 1	Active, not recruiting	February 2019	United States, Minnesota ... 展开 >> Children's Hospitals and Clinics of Minnesota Minneapolis, Minnesota, United States, 55404 United States, Wisconsin Children's Hospital of Wisconsin Milwaukee, Wisconsin, United States, 53226 收起 <<
NCT00424775	Neoplasms	Phase 1	Terminated	-	-
NCT00750178	Cancer, Advanced	Phase 1	Completed	-	-
NCT00097929	B-cell Lymphoma	Phase 2	Completed	-	-
NCT00126451	Breast Cancer ... 展开 >> Colorectal Cancer Non-small-cell Lung Carcinoma 收起 <<	Phase 2	Terminated	-	-
NCT00091559	Cutaneous T-cell Lymphoma ... 展开 >> Sezary Syndrome Mycosis Fungoides 收起 <<	Phase 2	Completed	-	-
NCT02475915	Acute HIV Infection	Phase 1 Phase 2	Completed	-	Thailand ... 展开 >> SEARCH, the Thai Red Cross AIDS Research Centre Bangkok, Thailand, 10330 收起 <<
NCT03713320	Cutaneous T-Cell Lymphoma/Myco... 展开 >>sis Fungoides 收起 <<	Phase 2	Recruiting	September 2021	United States, California ... 展开 >> City of Hope Recruiting Duarte, California, United States, 91010 Contact: Rosemarie Abary 626-218-8087 rabary@coh.org Principal Investigator: Christiane Querfeld, MD Chao Family Comprehensive Cancer Center at University of California, Irvine Recruiting Orange, California, United States, 92868 Contact: Blake Johnson 714-456-3476 Blakej@uci.edu Principal Investigator: Lauren Pinter-Brown, MD United States, Connecticut Smilow Cancer Hospital at Yale-New Haven Not yet recruiting New Haven, Connecticut, United States, 06510 Principal Investigator: Francine Foss, MD United States, Florida Moffitt Cancer Center Not yet recruiting Tampa, Florida, United States, 33612 Principal Investigator: Lubomir Sokol, MD, PhD United States, Missouri Washington University School of Medicine Recruiting Saint Louis, Missouri, United States, 63108 Contact: Mary Tabacchi, CCRC 314-362-8171 mtabacch@wustl.edu Principal Investigator: Amy Musiek, MD United States, New York Rochester Skin Lymphoma Medical Group Not yet recruiting Fairport, New York, United States, 14450 Principal Investigator: Brian Poligone, MD, PhD United States, Ohio The Ohio State University Comprehensive Cancer Center Not yet recruiting Columbus, Ohio, United States, 43210 Principal Investigator: Basem William, MD Canada, Alberta Cross Cancer Institute Not yet recruiting Edmonton, Alberta, Canada, T6G 1Z2 Principal Investigator: Minakshi Taparia, MD Canada, Ontario Princess Margaret Cancer Centre Not yet recruiting Toronto, Ontario, Canada, M5G 2C1 Principal Investigator: Vishal Kukreti, MD Canada, Quebec Jewish General Hospital Not yet recruiting Montréal, Quebec, Canada, H3T 1E2 Principal Investigator: Kevin Pehr, MD 收起 <<
NCT00127101	Lymphoma	Phase 1	Terminated(The study was stopp... 展开 >>ed due to low enrollment.) 收起 <<	-	-
NCT00127101	-		Terminated(The study was stopp... 展开 >>ed due to low enrollment.) 收起 <<	-	-
NCT02395627	Breast Neoplasms	Phase 2	Recruiting	August 1, 2019	United States, California ... 展开 >> University of California, San Francisco Medical Center Recruiting San Francisco, California, United States, 94115 Contact: Amy DeLuca 877-827-3222 cancertrials@ucsf.edu Principal Investigator: Pamela Munster, MD 收起 <<
NCT00217412	Childhood Acute Promyelocytic ... 展开 >>Leukemia (M3) Childhood Atypical Teratoid/Rhabdoid Tumor Childhood Burkitt Lymphoma Childhood Chronic Myelogenous Leukemia Childhood Diffuse Large Cell Lymphoma Childhood Immunoblastic Large Cell Lymphoma Juvenile Myelomonocytic Leukemia Recurrent Childhood Acute Lymphoblastic Leukemia Recurrent Childhood Acute Myeloid Leukemia Recurrent Childhood Grade III Lymphomatoid Granulomatosis Recurrent Childhood Large Cell Lymphoma Recurrent Childhood Lymphoblastic Lymphoma Recurrent Childhood Medulloblastoma Recurrent Childhood Small Noncleaved Cell Lymphoma Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor Recurrent Neuroblastoma Recurrent/Refractory Childhood Hodgkin Lymphoma Relapsing Chronic Myelogenous Leukemia Unspecified Childhood Solid Tumor, Protocol Specific 收起 <<	Phase 1	Completed	-	United States, Pennsylvania ... 展开 >> Children's Oncology Group Philadelphia, Pennsylvania, United States, 19104 收起 <<
NCT00816283	Leukemia	Phase 1	Completed	-	United States, California ... 展开 >> City of Hope Comprehensive Cancer Center Duarte, California, United States, 91010-3000 City of Hope Medical Group Pasadena, California, United States, 91105 收起 <<
NCT02409134	-		Completed	-	United States, Michigan ... 展开 >> University of Michigan Health System Ann Arbor, Michigan, United States, 48109 收起 <<
NCT00875056	Lymphoma	Phase 2	Active, not recruiting	January 31, 2019	-
NCT00005634	Leukemia Lymp... 展开 >>homa Multiple Myeloma and Plasma Cell Neoplasm Prostate Cancer Small Intestine Cancer Unspecified Adult Solid Tumor, Protocol Specific 收起 <<	Phase 1	Completed	-	United States, New York ... 展开 >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 收起 <<
NCT00310024	Refractory Multiple Myeloma ... 展开 >> Stage I Multiple Myeloma Stage II Multiple Myeloma Stage III Multiple Myeloma 收起 <<	Phase 1	Completed	-	United States, Maryland ... 展开 >> University of Maryland Greenebaum Cancer Center Baltimore, Maryland, United States, 21201-1595 收起 <<
NCT01983969	Advanced Cancers ... 展开 >> Lymphoma 收起 <<	Phase 1 Phase 2	Completed	-	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT02035137	Neuroblastoma	Phase 2	Recruiting	December 2019	United States, California ... 展开 >> Childrens Hospital Los Angeles Recruiting Los Angeles, California, United States, 90027-0700 Contact: Araz Marachelian, MD 323-361-5687 amarachelian@chla.usc.edu Lucile Salter Packer Children's Hospital Recruiting Palo Alto, California, United States, 94304 Contact: Sheri Spunt, MD UCSF Helen Diller Family Comprehensive Cancer Center Recruiting San Francisco, California, United States, 94115 Contact: Katherine Matthay, MD 415-476-3831 matthayK@peds.ucsf.edu United States, Colorado Children Hospital of Colorado Recruiting Aurora, Colorado, United States, 80045 Contact: Margaret Macy, MD 720-777-8856 Margaret.macy@childrenscolorado.org United States, Georgia AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus Recruiting Atlanta, Georgia, United States, 30322 Contact: Kelly Goldsmith, MD 404-785-0853 kgoldsm@emory.edu United States, Illinois University of Chicago, Comer Children's Hospital Recruiting Chicago, Illinois, United States, 60637 Contact: Ami Desai, MD 773-843-3943 adesai12@peds.bsd.uchicago.edu United States, Massachusetts Children's Hospital Boston Recruiting Boston, Massachusetts, United States, 02115 Contact: Suzanne Shusterman, MD 617-632-4901 United States, Michigan C.S Mott Children's Hospital Recruiting Ann Arbor, Michigan, United States, 48109 Contact: Gregory Yanik, MD 734-936-8785 gyanik@umich.edu United States, North Carolina University of North Carolina Not yet recruiting Chapel Hill, North Carolina, United States, 27599 Contact: Patrick Thompson, MD patom@email.unc.edu United States, Ohio Cincinnati Children's Hospital Medical Center Recruiting Cincinnati, Ohio, United States, 45229-3039 Contact: Brian Weiss, MD 513-636-9863 brian.weiss@chmcc.org United States, Pennsylvania Children's Hospital of Philadelphia Recruiting Philadelphia, Pennsylvania, United States, 19104-4318 Contact: Yael Mosse, MD 215-590-0965 mosse@chop.edu United States, Texas Cook Children's Healthcare System Recruiting Fort Worth, Texas, United States, 76104 Contact: Meaghan Granger, MD 682-885-4007 United States, Washington Seattle Children's Hospital Recruiting Seattle, Washington, United States, 98105 Contact: Navin Pinto, MD 206-987-5783 navin.pinto@seattlechildrens.org Canada, Ontario Hospital for Sick Children Recruiting Toronto, Ontario, Canada, M5G1X8 Contact: Meredith Irwin, MD 收起 <<
NCT00109109	Multiple Myeloma	Phase 1	Terminated	-	-
NCT00423449	Non-Small Cell Lung Cancer	Phase 1	Completed	-	-
NCT00423449	-		Completed	-	-
NCT00574587	Breast Cancer	Phase 1 Phase 2	Unknown	January 2016	United States, New York ... 展开 >> Montefiore Medical Center Bronx, New York, United States, 10461 收起 <<
NCT00589472	Prostate Adenocarcinoma ... 展开 >> Stage I Prostate Cancer Stage IIA Prostate Cancer Stage IIB Prostate Cancer Stage III Prostate Cancer 收起 <<	Phase 2	Completed	-	United States, California ... 展开 >> UCLA / Jonsson Comprehensive Cancer Center Los Angeles, California, United States, 90095 UCSF Medical Center-Parnassus San Francisco, California, United States, 94143 United States, Illinois University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States, 60637 United States, Maryland Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States, 21287 United States, Massachusetts Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, Michigan University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States, 48109 Wayne State University/Karmanos Cancer Institute Detroit, Michigan, United States, 48201 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, New Jersey UMDNJ - New Jersey Medical School Newark, New Jersey, United States, 07103 United States, New York Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27710 United States, Oregon Oregon Health and Science University Portland, Oregon, United States, 97239 United States, Texas M D Anderson Cancer Center Houston, Texas, United States, 77030 United States, Washington University of Washington Medical Center Seattle, Washington, United States, 98195 United States, Wisconsin University of Wisconsin Hospital and Clinics Madison, Wisconsin, United States, 53792 收起 <<
NCT02943642	Mycosis Fungoides	Phase 2	Not yet recruiting	May 2020	-
NCT00589472	-		Completed	-	-
NCT00473889	Stage IIIB or IV Non-Small Cel... 展开 >>l Lung Cancer 收起 <<	Phase 2 Phase 3	Terminated(The study was termi... 展开 >>nated based on the recommendation by the DSMB following a pre-planned protocol interim analysis because the endpoint was not achieved.) 收起 <<	-	-
NCT01554852	Multiple Myeloma	Phase 3	Active, not recruiting	December 2022	United Kingdom ... 展开 >> 112 sites UK wide United Kingdom, United Kingdom 收起 <<
NCT00455351	Pelvic Cancer ... 展开 >> Radiotherapy 收起 <<	Phase 1	Completed	-	Norway ... 展开 >> The Norwegian Radium Hospital Oslo, Norway, NO-0310 收起 <<
NCT00045006	Cancer	Phase 1	Completed	-	United States, New York ... 展开 >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 收起 <<
NCT00537121	Esophageal Cancer ... 展开 >> Gastric Cancer Liver Cancer 收起 <<	Phase 1	Completed	-	United States, New York ... 展开 >> Roswell Park Cancer Institute Buffalo, New York, United States, 14263-0001 收起 <<
NCT01076530	Childhood Atypical Teratoid/Rh... 展开 >>abdoid Tumor Childhood Central Nervous System Choriocarcinoma Childhood Central Nervous System Embryonal Tumor Childhood Central Nervous System Germinoma Childhood Central Nervous System Mixed Germ Cell Tumor Childhood Central Nervous System Teratoma Childhood Central Nervous System Yolk Sac Tumor Childhood Choroid Plexus Tumor Childhood Craniopharyngioma Childhood Ependymoblastoma Childhood Grade I Meningioma Childhood Grade II Meningioma Childhood Grade III Meningioma Childhood High-grade Cerebellar Astrocytoma Childhood High-grade Cerebral Astrocytoma Childhood Infratentorial Ependymoma Childhood Low-grade Cerebellar Astrocytoma Childhood Low-grade Cerebral Astrocytoma Childhood Medulloepithelioma Childhood Mixed Glioma Childhood Oligodendroglioma Childhood Supratentorial Ependymoma Extra-adrenal Paraganglioma Recurrent Childhood Brain Stem Glioma Recurrent Childhood Central Nervous System Embryonal Tumor Recurrent Childhood Cerebellar Astrocytoma Recurrent Childhood Cerebral Astrocytoma Recurrent Childhood Ependymoma Recurrent Childhood Medulloblastoma Recurrent Childhood Pineoblastoma Recurrent Childhood Spinal Cord Neoplasm Recurrent Childhood Subependymal Giant Cell Astrocytoma Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor Recurrent Childhood Visual Pathway and Hypothalamic Glioma 收起 <<	Phase 1	Completed	-	United States, Illinois ... 展开 >> Childrens Memorial Hospital Chicago, Illinois, United States, 60614 United States, Michigan C S Mott Children's Hospital Ann Arbor, Michigan, United States, 48109 United States, Minnesota University of Minnesota Medical Center-Fairview Minneapolis, Minnesota, United States, 55455 United States, Oregon Oregon Health and Science University Portland, Oregon, United States, 97239 United States, Tennessee St. Jude Children's Research Hospital Memphis, Tennessee, United States, 38105 United States, Texas Baylor College of Medicine Houston, Texas, United States, 77030 United States, Washington Seattle Children's Hospital Seattle, Washington, United States, 98105 Canada, Ontario Hospital for Sick Children Toronto, Ontario, Canada, M5G 1X8 Canada, Quebec Hospital Sainte-Justine Montreal, Quebec, Canada, H3T 1C5 收起 <<
NCT01386398	Lymphoma	Phase 3	Withdrawn(Company withdrew int... 展开 >>erest) 收起 <<	-	-
NCT00324870	Clear Cell Renal Cell Carcinom... 展开 >>a Recurrent Renal Cell Cancer Stage III Renal Cell Cancer Stage IV Renal Cell Cancer 收起 <<	Phase 1 Phase 2	Completed	-	United States, Maryland ... 展开 >> Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States, 21287 Peninsula Oncology and Hematology PA Salisbury, Maryland, United States, 21801 United States, Wisconsin University of Wisconsin Hospital and Clinics Madison, Wisconsin, United States, 53792 收起 <<
NCT00127127	Tumors	Phase 1	Completed	-	-
NCT02083250	Acute Lymphoblastic Leukemia i... 展开 >>n Remission Acute Myeloid Leukemia in Remission Allogeneic Hematopoietic Stem Cell Transplantation Recipient Myelodysplastic Syndrome Previously Treated Myelodysplastic Syndrome Recurrent Acute Lymphoblastic Leukemia Recurrent Acute Myeloid Leukemia 收起 <<	Phase 1	Active, not recruiting	March 30, 2021	United States, Texas ... 展开 >> M D Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT00324870	-		Completed	-	-
NCT01802333	Acute Myeloid Leukemia ... 展开 >> Untreated Adult Acute Myeloid Leukemia 收起 <<	Phase 3	Completed	-	-
NCT03263936	Acute Myelogenous Leukemia	Phase 1	Recruiting	July 2020	-
NCT00555399	Glioblastoma Multiforme ... 展开 >> Anaplastic Glioma 收起 <<	Phase 1 Phase 2	Active, not recruiting	November 2019	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT01483690	Acute Lymphoblastic Leukemia ... 展开 >> Precursor B-Cell Lymphoblastic Leukemia Precursor T-Cell Lymphoblastic Leukemia 收起 <<	Phase 1 Phase 2	Terminated(Toxicity)	-	-
NCT00473889	-		Terminated(The study was termi... 展开 >>nated based on the recommendation by the DSMB following a pre-planned protocol interim analysis because the endpoint was not achieved.) 收起 <<	-	-
NCT00601718	-		Completed	-	-
NCT00616967	Breast Cancer	Phase 2	Completed	-	United States, Alabama ... 展开 >> University of Alabama Comprehensive Cancer Center Birmingham, Alabama, United States, 35249 United States, Indiana Indiana University Purdue University of Indianapolis Indianapolis, Indiana, United States, 46202 United States, Maryland Anne Arundel Health System Annapolis, Maryland, United States, 21401 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore, Maryland, United States, 21231-2410 United States, Minnesota Mayo Clinic Cancer Center Rochester, Minnesota, United States, 55905 收起 <<
NCT00764517	-		Completed	-	-
NCT00616967	-		Completed	-	-
NCT00258349	Breast Cancer ... 展开 >> Male Breast Cancer Recurrent Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer Stage IV Breast Cancer 收起 <<	Phase 1 Phase 2	Completed	-	United States, Alabama ... 展开 >> University of Alabama at Birmingham Birmingham, Alabama, United States, 35294 United States, Iowa Mercy Capitol Des Moines, Iowa, United States, 50307 Iowa Methodist Medical Center Des Moines, Iowa, United States, 50309 Iowa Oncology Research Association CCOP Des Moines, Iowa, United States, 50309 Medical Oncology and Hematology Associates-Des Moines Des Moines, Iowa, United States, 50309 Medical Oncology and Hematology Associates Des Moines, Iowa, United States, 50314 Mercy Medical Center - Des Moines Des Moines, Iowa, United States, 50314 Iowa Lutheran Hospital Des Moines, Iowa, United States, 50316 Siouxland Hematology Oncology Associates Sioux City, Iowa, United States, 51101 Mercy Medical Center-Sioux City Sioux City, Iowa, United States, 51104 Saint Luke's Regional Medical Center Sioux City, Iowa, United States, 51104 United States, Maryland Johns Hopkins University Baltimore, Maryland, United States, 21287-8936 United States, Massachusetts Eastern Cooperative Oncology Group Boston, Massachusetts, United States, 02215 United States, Minnesota Hutchinson Area Health Care Hutchinson, Minnesota, United States, 55350 Meeker County Memorial Hospital Litchfield, Minnesota, United States, 55355 Saint John's Hospital - Healtheast Maplewood, Minnesota, United States, 55109 Virginia Piper Cancer Institute Minneapolis, Minnesota, United States, 55407 Hennepin County Medical Center Minneapolis, Minnesota, United States, 55415 Regions Hospital Saint Paul, Minnesota, United States, 55101 Saint Joseph's Hospital - Healtheast Saint Paul, Minnesota, United States, 55102 Saint Francis Regional Medical Center Shakopee, Minnesota, United States, 55379 Woodwinds Health Campus Woodbury, Minnesota, United States, 55125 United States, New York Albert Einstein College of Medicine Bronx, New York, United States, 10461 Montefiore Medical Center Bronx, New York, United States, 10467-2490 Saint Vincent's Hospital and Medical Center of New York New York, New York, United States, 10011 收起 <<
NCT00764517	Recurrent B-Cell Non-Hodgkin L... 展开 >>ymphoma Recurrent Chronic Lymphocytic Leukemia Recurrent Indolent Adult Non-Hodgkin Lymphoma Refractory B-Cell Non-Hodgkin Lymphoma 收起 <<	Phase 2	Completed	-	United States, Oregon ... 展开 >> OHSU Knight Cancer Institute Portland, Oregon, United States, 97239 United States, Pennsylvania Penn State Milton S Hershey Medical Center Hershey, Pennsylvania, United States, 17033-0850 收起 <<
NCT01801670	-		Withdrawn(Enrollment was too s... 展开 >>low, so no participants were ever enrolled.) 收起 <<	January 2015	United States, Massachusetts ... 展开 >> Boston University Boston, Massachusetts, United States, 02118 收起 <<
NCT00601718	Adult Nasal Type Extranodal NK... 展开 >>/T-cell Lymphoma Anaplastic Large Cell Lymphoma Angioimmunoblastic T-cell Lymphoma Contiguous Stage II Mantle Cell Lymphoma Cutaneous B-cell Non-Hodgkin Lymphoma Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue Nodal Marginal Zone B-cell Lymphoma Noncontiguous Stage II Mantle Cell Lymphoma Recurrent Adult Burkitt Lymphoma Recurrent Adult Diffuse Large Cell Lymphoma Recurrent Adult Diffuse Mixed Cell Lymphoma Recurrent Adult Diffuse Small Cleaved Cell Lymphoma Recurrent Adult Grade III Lymphomatoid Granulomatosis Recurrent Adult Hodgkin Lymphoma Recurrent Adult Immunoblastic Large Cell Lymphoma Recurrent Adult Lymphoblastic Lymphoma Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Grade 3 Follicular Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Marginal Zone Lymphoma Recurrent Mycosis Fungoides/Sezary Syndrome Recurrent Small Lymphocytic Lymphoma Splenic Marginal Zone Lymphoma Stage I Cutaneous T-cell Non-Hodgkin Lymphoma Stage I Mantle Cell Lymphoma Stage I Mycosis Fungoides/Sezary Syndrome Stage II Cutaneous T-cell Non-Hodgkin Lymphoma Stage II Mycosis Fungoides/Sezary Syndrome Stage III Cutaneous T-cell Non-Hodgkin Lymphoma Stage III Mantle Cell Lymphoma Stage III Mycosis Fungoides/Sezary Syndrome Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma Stage IV Mantle Cell Lymphoma Stage IV Mycosis Fungoides/Sezary Syndrome Waldenström Macroglobulinemia 收起 <<	Phase 1 Phase 2	Completed	-	United States, Washington ... 展开 >> Puget Sound Oncology Consortium Seattle, Washington, United States, 98109 收起 <<
NCT00258349	-		Completed	-	-
NCT00867178	Medulloblastoma ... 展开 >> Pineoblastoma Supratentorial Embryonal Tumor, Not Otherwise Specified Untreated Childhood Medulloblastoma Untreated Childhood Pineoblastoma Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor 收起 <<	Not Applicable	Active, not recruiting	-	United States, California ... 展开 >> Children's Hospital Los Angeles Los Angeles, California, United States, 90027 Lucile Packard Children's Hospital Stanford University Palo Alto, California, United States, 94304 United States, District of Columbia Children's National Medical Center Washington, District of Columbia, United States, 20010 United States, Illinois Lurie Children's Hospital-Chicago Chicago, Illinois, United States, 60611 United States, Maryland National Cancer Institute Pediatric Oncology Branch Bethesda, Maryland, United States, 20892 United States, New York Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27710 United States, Ohio Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States, 45229 United States, Pennsylvania Children's Hospital of Philadelphia Philadelphia, Pennsylvania, United States, 19104 Children's Hospital of Pittsburgh of UPMC Pittsburgh, Pennsylvania, United States, 15224 United States, Tennessee Pediatric Brain Tumor Consortium Memphis, Tennessee, United States, 38105 St. Jude Children's Research Hospital Memphis, Tennessee, United States, 38105 United States, Texas M D Anderson Cancer Center Houston, Texas, United States, 77030 Texas Children's Hospital Houston, Texas, United States, 77030 United States, Washington Seattle Children's Hospital Seattle, Washington, United States, 98105 收起 <<
NCT00357305	Accelerated Phase Chronic Myel... 展开 >>ogenous Leukemia Adult Acute Basophilic Leukemia Adult Acute Eosinophilic Leukemia Adult Acute Megakaryoblastic Leukemia (M7) Adult Acute Minimally Differentiated Myeloid Leukemia (M0) Adult Acute Monoblastic Leukemia (M5a) Adult Acute Monocytic Leukemia (M5b) Adult Acute Myeloblastic Leukemia With Maturation (M2) Adult Acute Myeloblastic Leukemia Without Maturation (M1) Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Adult Acute Myelomonocytic Leukemia (M4) Adult Acute Promyelocytic Leukemia (M3) Adult Erythroleukemia (M6a) Adult Pure Erythroid Leukemia (M6b) Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative Blastic Phase Chronic Myelogenous Leukemia Chronic Eosinophilic Leukemia Chronic Myelomonocytic Leukemia Chronic Neutrophilic Leukemia de Novo Myelodysplastic Syndromes Essential Thrombocythemia Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable Polycythemia Vera Previously Treated Myelodysplastic Syndromes Primary Myelofibrosis Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Adult Acute Myeloid Leukemia Relapsing Chronic Myelogenous Leukemia Secondary Acute Myeloid Leukemia Secondary Myelodysplastic Syndromes 收起 <<	Phase 1	Completed	-	United States, Maryland ... 展开 >> University of Maryland Greenebaum Cancer Center Baltimore, Maryland, United States, 21201-1595 United States, Pennsylvania University of Pittsburgh Pittsburgh, Pennsylvania, United States, 15232 收起 <<
NCT01153672	-		Completed	-	-
NCT01501370	Multiple Myeloma	Phase 2	Withdrawn	-	Italy ... 展开 >> Clinica di Ematologia, A.O.U. Ospedali Riuniti, Ospedale Umberto I di Ancona Ancona, Italy, 60020 U.O.S. di Ematologia, Ospedale Mazzoni Ascoli Piceno, Italy, 63100 Dh ematologia, A.O.U. Careggi Firenze, Italy, 50139 Ematologia, Ospedale S. Maria della Misericordia Perugia, Italy, 06156 Ematologia e Immunoematologia, Azienda Ospedaliera Riuniti Marche Nord Pesaro, Italy, 61100 Dip. Ematologia-U.O di Ematologia Generale-Azienda USL di Pescara-P.O. dello Spirito Santo Pescara, Italy, 65100 Ematologia , A.O.U. Pisana Pisa, Italy, 56126 Universitaria di Ematologia, A.O.U. San Giovanni Battista di Torino, Torino, Italy, 10126 收起 <<
NCT01153672	Male Breast Cancer ... 展开 >> Recurrent Breast Cancer Stage IV Breast Cancer 收起 <<	Not Applicable	Completed	-	United States, Washington ... 展开 >> Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington, United States, 98109 收起 <<

Vorinostat/伏立诺他 {[allProObj[0].p_purity_real_show]}

Vorinostat/伏立诺他纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Vorinostat/伏立诺他质控信息

Vorinostat/伏立诺他生物活性

Vorinostat/伏立诺他细胞实验

Vorinostat/伏立诺他动物实验

Vorinostat/伏立诺他动物研究

Vorinostat/伏立诺他临床研究

Vorinostat/伏立诺他参考文献

Vorinostat/伏立诺他实验方案

Vorinostat/伏立诺他技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Vorinostat/伏立诺他 {[allProObj[0].p_purity_real_show]}

Vorinostat/伏立诺他 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Vorinostat/伏立诺他 质控信息

Vorinostat/伏立诺他 生物活性

Vorinostat/伏立诺他 细胞实验

Vorinostat/伏立诺他 动物实验

Vorinostat/伏立诺他 动物研究

Vorinostat/伏立诺他 临床研究

Vorinostat/伏立诺他 参考文献

Vorinostat/伏立诺他 实验方案

Vorinostat/伏立诺他 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Vorinostat/伏立诺他纯度/质量文件产品仅供科研

Vorinostat/伏立诺他质控信息

Vorinostat/伏立诺他生物活性

Vorinostat/伏立诺他细胞实验

Vorinostat/伏立诺他动物实验

Vorinostat/伏立诺他动物研究

Vorinostat/伏立诺他临床研究

Vorinostat/伏立诺他参考文献

Vorinostat/伏立诺他实验方案

Vorinostat/伏立诺他技术信息